cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"In a white male patient with bladder urothelial carcinoma, whose tumor biopsy transcriptomic profile of the immune microenvironment reveals relevant characteristics and a tumor mutational burden of 18.0, what is the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose tumor biopsy transcriptomic profile of the immune microenvironment reveals relevant characteristics and a tumor mutational burden of 18.0, what is the likelihood of a favorable response to Atezolizumab therapy? Assess the tumor microenvironment’s transcriptomic profile using the COMPASS tool, specifically examining markers related to immune deficiency—namely natural killer cells, exhausted T cells, B cells, and plasma cells. Integrate these findings with the COMPASS output to provide an evidence-based assessment of the patient’s likely response to treatment. Ensure your analysis includes relevant transcriptomic features that highlight the state of immune activity within the tumor.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 1.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 1.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS tool to evaluate the tumor microenvironment's transcriptomic profile, with a particular focus on markers that reflect immune deficiency—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these findings with the overall COMPASS results to provide an evidence-based prediction of the patient’s response to treatment. Ensure your analysis highlights relevant transcriptomic features that indicate the current state of immune activity within the tumor.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"For my Caucasian female patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and noted a tumor mutational burden of 44.0. Based on these findings, how likely is she to respond positively to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and noted a tumor mutational burden of 44.0. Based on these findings, how likely is she to respond positively to Atezolizumab therapy? Please use the COMPASS tool to analyze the transcriptomic profile of the tumor microenvironment. Focus specifically on immune markers associated with immune deficiency, such as natural killer cells, exhausted T cells, B cells, and plasma cells. After evaluating these markers, integrate your findings with the overall COMPASS results to generate an evidence-based prediction of the patient’s response to treatment. Be sure to emphasize transcriptomic features that accurately reflect the current state of immune activity within the tumor.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy. With a tumor mutational burden of 2.0, what is the anticipated efficacy of Atezolizumab therapy in this case?","For a white female patient diagnosed with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy. With a tumor mutational burden of 2.0, what is the anticipated efficacy of Atezolizumab therapy in this case? Please analyze the tumor microenvironment's transcriptomic profile using the COMPASS tool. Specifically, focus on immune markers that indicate deficiencies, including natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers have been evaluated, combine your findings with the broader COMPASS results to formulate an evidence-based prediction of the patient's treatment response. Be sure to highlight transcriptomic features that accurately portray the current immune activity within the tumor.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"For a white male patient diagnosed with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 8.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 8.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Please perform a transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Focus specifically on immune markers that may indicate deficiencies—for example, assessing levels of natural killer cells, exhausted T cells, B cells, and plasma cells. After evaluating these markers, integrate your findings with the overall results from COMPASS to develop an evidence-based prediction of the patient’s treatment response. In your analysis, make sure to clearly highlight transcriptomic features that reflect the current status of immune activity within the tumor.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"For a white female patient with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 6.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 6.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Conduct a transcriptomic analysis of the tumor microenvironment using the COMPASS tool, with particular attention to immune markers that may indicate immunological deficiencies. Specifically, quantify markers such as natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers have been evaluated, integrate the findings with the overall COMPASS analysis to formulate an evidence-based prediction of the patient’s treatment response. Be sure to clearly identify and document transcriptomic features that reflect the current status of immune activity within the tumor.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11.0 based on transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11.0 based on transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Perform a comprehensive transcriptomic evaluation of the tumor microenvironment using the COMPASS tool. Focus on assessing immune markers that could suggest immunological deficits, specifically quantifying natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers have been measured, integrate the results with the overall COMPASS analysis to develop an evidence-based prediction of the patient’s treatment response. Ensure that you clearly document all transcriptomic features that indicate the current immune activity within the tumor.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 18 and transcriptomic profiling of his tumor immune microenvironment obtained from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 18 and transcriptomic profiling of his tumor immune microenvironment obtained from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please perform a detailed transcriptomic analysis of the tumor microenvironment using the COMPASS tool. In this evaluation, focus on quantifying key immune markers—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess any potential immunological deficiencies. After obtaining these measurements, integrate the findings with the overall COMPASS analysis to predict the patient's treatment response based on sound evidence. Ensure that all transcriptomic data reflecting current immune activity within the tumor are thoroughly documented.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"For my white female patient with bladder urothelial carcinoma, we obtained a transcriptomic assessment of the tumor immune microenvironment from her bladder biopsy. Given that her tumor mutation burden is reported as “nan,” what is the likelihood of a favorable response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, we obtained a transcriptomic assessment of the tumor immune microenvironment from her bladder biopsy. Given that her tumor mutation burden is reported as “nan,” what is the likelihood of a favorable response to Atezolizumab therapy? Please conduct a comprehensive transcriptomic evaluation of the tumor microenvironment using the COMPASS tool. In this assessment, quantify specific immune markers—including natural killer cells, exhausted T cells, B cells, and plasma cells—to identify any immunological deficits. Once these measurements are obtained, integrate them with the overall COMPASS analysis to predict the patient's treatment response, ensuring that the conclusions are based on robust evidence. Additionally, thoroughly document all transcriptomic data related to the current immune activity within the tumor.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment via a needle biopsy. The tumor has a tumor mutation burden (TMB) of nan. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment via a needle biopsy. The tumor has a tumor mutation burden (TMB) of nan. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Please perform a detailed transcriptomic analysis of the tumor microenvironment using the COMPASS tool. In this assessment, precisely quantify immune markers—including natural killer cells, exhausted T cells, B cells, and plasma cells—to determine any deficits in immune function. Then, integrate these marker measurements with the broader COMPASS analysis to generate an evidence-based prediction regarding the patient’s treatment response. Finally, ensure that all transcriptomic data related to the current immune activity within the tumor is thoroughly documented.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via transcriptomics from a kidney biopsy and who has a tumor mutational burden of 2.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via transcriptomics from a kidney biopsy and who has a tumor mutational burden of 2.0, what is the estimated likelihood of a positive response to atezolizumab therapy? Please conduct a comprehensive transcriptomic analysis of the tumor microenvironment using the COMPASS tool. In this analysis, accurately quantify key immune markers—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to assess for any potential impairments in immune function. Integrate these quantitative marker assessments with the wider COMPASS dataset to formulate an evidence-based prediction of the patient’s response to treatment. Finally, ensure detailed and systematic documentation of all transcriptomic data related to current immune activity within the tumor.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"For a Caucasian patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 8.0, and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a Caucasian patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 8.0, and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Conduct a thorough transcriptomic evaluation of the tumor microenvironment using the COMPASS tool. Accurately quantify key immune markers—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess potential weaknesses in the immune response. Combine these quantitative results with the broader COMPASS dataset to develop an evidence-based prediction of the patient’s treatment response. Finally, document all transcriptomic data related to current immune activity within the tumor systematically and in detail.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"For my White female patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, and her tumor mutation burden is currently unknown. Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy?","For my White female patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, and her tumor mutation burden is currently unknown. Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy? Please perform a comprehensive transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Accurately quantify key immune cell populations—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—so as to identify any shortcomings in the immune response. Integrate these quantitative findings with the complete COMPASS dataset to create an evidence-based prediction regarding the patient's treatment response. Finally, ensure that all transcriptomic data related to the tumor's immune activity are thoroughly and systematically documented.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"For a Caucasian male with bladder urothelial carcinoma who has a tumor mutational burden of 9.0 based on a ureter biopsy transcriptomic analysis of the tumor immune microenvironment, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male with bladder urothelial carcinoma who has a tumor mutational burden of 9.0 based on a ureter biopsy transcriptomic analysis of the tumor immune microenvironment, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS tool to conduct a detailed transcriptomic analysis of the tumor microenvironment. Focus on accurately quantifying key immune cell populations—namely, natural killer cells, exhausted T cells, B cells, and plasma cells—to detect any potential deficiencies in the immune response. Then, integrate these quantitative findings with the entire COMPASS dataset to generate an evidence-based prediction of the patient’s treatment response. Finally, ensure that all transcriptomic data regarding the tumor's immune activity are comprehensively documented in a systematic manner.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"For my white female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 4.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the anticipated response rate to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 4.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the anticipated response rate to Atezolizumab therapy? Please use the COMPASS tool to perform a detailed transcriptomic analysis of the tumor microenvironment. Specifically, quantify key immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess for potential deficiencies within the immune response. Next, integrate these quantitative results with the full COMPASS dataset to formulate an evidence-based prediction of the patient’s treatment response. Finally, document all findings regarding the tumor's immune activity systematically.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"For my white male patient with bladder urothelial carcinoma, analysis of the tumor immune microenvironment from a ureter biopsy reveals a tumor mutational burden of 32.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, analysis of the tumor immune microenvironment from a ureter biopsy reveals a tumor mutational burden of 32.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Utilize the COMPASS tool to conduct a comprehensive transcriptomic evaluation of the tumor’s microenvironment. Begin by quantifying critical immune cell populations—namely, natural killer cells, exhausted T cells, B cells, and plasma cells—to identify any potential immune response deficiencies. Once you have these quantitative measures, integrate them with the complete COMPASS dataset to generate a data-driven prediction of the patient’s likely treatment response. Finally, ensure that you thoroughly document all observations regarding the tumor’s immune activity.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"For my Caucasian patient with bladder urothelial carcinoma, the tumor transcriptomic profile from the bladder biopsy indicates a tumor mutational burden (TMB) of 21.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, the tumor transcriptomic profile from the bladder biopsy indicates a tumor mutational burden (TMB) of 21.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please proceed with a transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Start by quantifying key immune cell populations—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to assess for any deficiencies in the immune response. After obtaining these quantitative measures, incorporate them into the full COMPASS dataset to develop a data-informed prediction of the patient’s likely response to treatment. Be sure to document all findings regarding the tumor's immune activity in detail.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 10.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 10.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please begin a transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Initially, quantify key immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate potential deficiencies in the immune response. Once you have these quantitative measures, integrate them into the complete COMPASS dataset to develop a predictive model for the patient’s treatment response. Ensure that all relevant findings regarding the tumor's immune activity are thoroughly documented.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"For a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 38.0. Based on this data, how likely is it that the patient will respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 38.0. Based on this data, how likely is it that the patient will respond favorably to Atezolizumab therapy? Begin a transcriptomic review of the tumor microenvironment using the COMPASS tool. Start by quantifying key immune cell subsets—specifically, natural killer cells, exhausted T cells, B cells, and plasma cells—to assess for possible deficiencies in the immune response. Next, incorporate these quantitative measures into the comprehensive COMPASS dataset to construct a predictive model of the patient’s treatment response. Finally, ensure that all significant observations related to the tumor’s immune activity are fully documented.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"For my Caucasian female patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and her tumor exhibits a TMB of 7.0. Based on these findings, what is the likelihood that she will have a positive response to atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and her tumor exhibits a TMB of 7.0. Based on these findings, what is the likelihood that she will have a positive response to atezolizumab therapy? Please initiate a transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Start by quantifying key immune cell subsets—namely natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate any deficiencies in the patient’s immune response. Then, incorporate these quantitative findings into the complete COMPASS dataset to build a predictive model for the treatment response. Finally, ensure that you document all significant observations regarding the tumor’s immune activity in detail.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment from his bladder biopsy reveals a tumor mutational burden of 5.0. Based on these findings, how likely is he to respond favorably to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment from his bladder biopsy reveals a tumor mutational burden of 5.0. Based on these findings, how likely is he to respond favorably to Atezolizumab therapy? Begin a transcriptomic analysis of the tumor microenvironment using the COMPASS tool. First, quantify the levels of natural killer cells, exhausted T cells, B cells, and plasma cells to assess any deficits in the patient's immune response. Next, incorporate these quantitative measurements into the overall COMPASS dataset to construct a predictive model for treatment response. Finally, carefully document all key observations regarding the tumor’s immune activity.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"For my white patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, which revealed a TMB of 15.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, which revealed a TMB of 15.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Initiate a transcriptomic evaluation of the tumor microenvironment with the COMPASS tool. Begin by quantifying natural killer cells, exhausted T cells, B cells, and plasma cells to identify potential deficiencies in the patient's immune response. Next, integrate these quantitative data into the comprehensive COMPASS dataset to develop a predictive model for treatment response. Finally, systematically document all critical observations concerning the tumor’s immune activity.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"In a white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. With the tumor mutation burden remaining undetermined, what is the likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. With the tumor mutation burden remaining undetermined, what is the likelihood of a positive response to Atezolizumab therapy? Begin a transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Start by quantifying specific immune cells—including natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate any deficiencies in the patient's immune response. Then, integrate these quantitative findings into the full COMPASS dataset to construct a predictive model for treatment response. Finally, carefully document all significant observations related to the tumor’s immune activity.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-181b63-ar-181b638.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA), we have obtained transcriptomic profiling of the tumor immune microenvironment from a lung biopsy. Given that the tumor mutational burden (TMB) is not measurable, how likely is the patient to respond to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), we have obtained transcriptomic profiling of the tumor immune microenvironment from a lung biopsy. Given that the tumor mutational burden (TMB) is not measurable, how likely is the patient to respond to Atezolizumab therapy? Initiate a transcriptomic evaluation of the tumor microenvironment with the COMPASS tool. First, quantify key immune cell populations—namely natural killer cells, exhausted T cells, B cells, and plasma cells—to identify any deficits in the patient’s immune response. Next, merge these quantitative data with the complete COMPASS dataset to develop a predictive model for treatment response. Lastly, thoroughly document all noteworthy findings related to the tumor’s immune characteristics.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and presents with a tumor mutation burden (TMB) of 18.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and presents with a tumor mutation burden (TMB) of 18.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please perform a transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Start by quantifying key immune cell populations—specifically, natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate for any deficiencies in the patient’s immune response. Then, integrate these quantitative findings with the complete COMPASS dataset to develop a predictive model for treatment response. Finally, ensure that all significant observations regarding the tumor’s immune profile are well documented.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"For my Black or African American male patient with bladder urothelial carcinoma, who has undergone a ureter biopsy yielding a transcriptomic profile of the tumor immune microenvironment and exhibits a tumor mutational burden of 7.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Black or African American male patient with bladder urothelial carcinoma, who has undergone a ureter biopsy yielding a transcriptomic profile of the tumor immune microenvironment and exhibits a tumor mutational burden of 7.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please conduct a transcriptomic analysis of the tumor microenvironment using the COMPASS platform. Begin by quantifying key immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess for any deficiencies in the patient's immune response. Next, integrate these quantitative measures with the full COMPASS dataset to construct a predictive model for treatment response. Finally, ensure that you document all significant findings related to the tumor's immune profile thoroughly.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutation burden (TMB) of 19.0. Based on these parameters, what is the likelihood that he will have a positive response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutation burden (TMB) of 19.0. Based on these parameters, what is the likelihood that he will have a positive response to atezolizumab therapy? Please perform a transcriptomic analysis of the tumor microenvironment using the COMPASS platform. Initially, quantify critical immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to determine if there are any deficiencies in the patient's immune response. Then, integrate these quantitative data with the complete COMPASS dataset to develop a predictive model for treatment response. Finally, document all key findings regarding the tumor's immune profile in detail.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment profiling reveals a tumor mutational burden of 5.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment profiling reveals a tumor mutational burden of 5.0, what is the likelihood of a favorable response to atezolizumab therapy? Conduct a transcriptomic evaluation of the tumor microenvironment using the COMPASS platform. Begin by quantifying critical immune cell subsets—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess for any potential deficiencies in the patient’s immune response. Then, combine these quantitative results with the complete COMPASS dataset to construct a predictive model for treatment response. Finally, provide a comprehensive documentation of all significant findings related to the tumor’s immune profile.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden of 5.0, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden of 5.0, what is the expected likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS platform to analyze the transcriptomic profile of the tumor microenvironment. First, quantify key immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the robustness of the patient’s immune response. Next, merge these quantitative findings with the complete COMPASS dataset to develop a predictive model of treatment response. Finally, compile a detailed report of all significant findings related to the tumor’s immune profile.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"In a white male patient with bladder urothelial carcinoma who has a tumor immune microenvironment transcriptomic profile from a bladder biopsy and a tumor mutation burden of 8.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who has a tumor immune microenvironment transcriptomic profile from a bladder biopsy and a tumor mutation burden of 8.0, what is the estimated likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to assess the tumor microenvironment's transcriptomic profile. Begin by quantifying key immune cell types, such as natural killer cells, exhausted T cells, B cells, and plasma cells, to gauge the patient’s immune response. Then, integrate these quantifications with the full COMPASS dataset to construct a predictive model for treatment response. Finally, prepare a comprehensive report summarizing all significant findings related to the tumor's immune profile.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"For a White female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden of 13.0. Based on this profile, what is her estimated likelihood of responding to Atezolizumab therapy?","For a White female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden of 13.0. Based on this profile, what is her estimated likelihood of responding to Atezolizumab therapy? Utilize the COMPASS platform to evaluate the tumor microenvironment’s transcriptomic profile. Start by quantifying critical immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the patient's immune response. Next, merge these quantifications with the complete COMPASS dataset to develop a predictive model for treatment response. Finally, compile a comprehensive report detailing all key findings related to the tumor's immune profile.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a TMB of 16.0 and whose tumor immune microenvironment was evaluated via transcriptomic profiling from a kidney biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a TMB of 16.0 and whose tumor immune microenvironment was evaluated via transcriptomic profiling from a kidney biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to analyze the tumor microenvironment's transcriptomic profile. Begin by quantifying key immune cell types—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the patient’s immune response. Then, integrate these measurements with the full COMPASS dataset to develop a model that predicts treatment response. Finally, prepare a detailed report summarizing all significant findings related to the tumor's immune profile.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment via kidney biopsy revealed a tumor mutation burden (TMB) of 2.0. Based on these findings, what is the likelihood of this patient responding favorably to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment via kidney biopsy revealed a tumor mutation burden (TMB) of 2.0. Based on these findings, what is the likelihood of this patient responding favorably to atezolizumab therapy? Please utilize the COMPASS platform to evaluate the transcriptomic landscape of the tumor microenvironment. Begin by quantifying specific immune cell populations, including natural killer cells, exhausted T cells, B cells, and plasma cells, to assess the patient’s immune response. Subsequently, merge these data with the complete COMPASS dataset to construct a predictive model for treatment response. Finally, generate a comprehensive report detailing all relevant findings concerning the tumor's immune profile.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"For a white female patient with bladder urothelial carcinoma, I obtained transcriptomic data of the tumor immune microenvironment from a bladder biopsy, and her tumor mutational burden (TMB) is reported as nan. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, I obtained transcriptomic data of the tumor immune microenvironment from a bladder biopsy, and her tumor mutational burden (TMB) is reported as nan. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to analyze the transcriptomic profile of the tumor microenvironment. Start by quantifying key immune cell populations, specifically natural killer cells, exhausted T cells, B cells, and plasma cells, to evaluate the patient’s immune response. Then, integrate these measurements with the full COMPASS dataset to develop a predictive model for the treatment response. Finally, compile a detailed report outlining the findings related to the tumor’s immune profile.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 7.0. Based on these findings, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 7.0. Based on these findings, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Begin by quantifying key immune cell populations—namely, natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the patient’s immune response. Next, integrate these quantifications with the complete COMPASS dataset in order to develop a predictive model for treatment response. Finally, prepare a detailed report summarizing the findings regarding the tumor’s immune profile.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 20.0, what is the estimated probability of achieving a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 20.0, what is the estimated probability of achieving a positive response to Atezolizumab therapy? Use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Start by quantifying specific immune cell populations, including natural killer cells, exhausted T cells, B cells, and plasma cells, to evaluate the patient's immune response. Then, incorporate these quantifications with the entire COMPASS dataset to build a predictive model for treatment outcomes. Finally, compile a comprehensive report detailing the tumor's immune profile and your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"For a white female patient with bladder urothelial carcinoma, whose tumor transcriptomic analysis from a bladder biopsy indicates a tumor mutational burden of 5.0 mutations/Mb, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose tumor transcriptomic analysis from a bladder biopsy indicates a tumor mutational burden of 5.0 mutations/Mb, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Begin by quantifying key immune cell populations, such as natural killer cells, exhausted T cells, B cells, and plasma cells, in order to assess the patient’s immune response. Next, integrate these quantifications with the full COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a detailed report that outlines the tumor’s immune profile and summarizes your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"For a White male patient with bladder urothelial carcinoma (BLCA) exhibiting a tumor mutational burden (TMB) of 38.0 and tumor immune microenvironment transcriptomic data from a bladder biopsy, what is the estimated probability of a favorable response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma (BLCA) exhibiting a tumor mutational burden (TMB) of 38.0 and tumor immune microenvironment transcriptomic data from a bladder biopsy, what is the estimated probability of a favorable response to Atezolizumab therapy? Please utilize the COMPASS platform to conduct a transcriptomic evaluation of the tumor microenvironment. Start by quantifying critical immune cell subsets—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the patient's immune response. After obtaining these measurements, integrate them with the full COMPASS dataset to construct a predictive model for treatment outcomes. Finally, compile a comprehensive report detailing the tumor's immune profile along with a summary of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"For a white male patient with bladder urothelial carcinoma who has undergone a kidney biopsy for transcriptomic analysis of the tumor immune microenvironment and has a tumor mutational burden of 6.0 mutations per megabase, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has undergone a kidney biopsy for transcriptomic analysis of the tumor immune microenvironment and has a tumor mutational burden of 6.0 mutations per megabase, what is the estimated likelihood of a favorable response to atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Begin by quantifying key immune cell subsets—including natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the patient's immune response. Once these measurements are obtained, incorporate them into the complete COMPASS dataset to build a predictive model for treatment outcomes. Finally, prepare a detailed report describing the tumor’s immune profile along with a summary of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile indicates a tumor mutational burden of 8.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile indicates a tumor mutational burden of 8.0, what is the estimated likelihood of a positive response to atezolizumab therapy? Please log into the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Begin by quantifying key immune cell populations, including natural killer cells, exhausted T cells, B cells, and plasma cells, to assess the patient’s immune response. Once these measurements are complete, integrate the data into the overall COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a detailed report that outlines the tumor’s immune profile and summarizes your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 13.0, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been performed. Based on these findings, what is the likelihood of achieving a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 13.0, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been performed. Based on these findings, what is the likelihood of achieving a positive response to Atezolizumab therapy? Please log into the COMPASS platform and carry out a transcriptomic evaluation of the tumor microenvironment. Start by quantifying essential immune cell populations—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to gauge the patient’s immune response. After obtaining these measurements, incorporate the data into the COMPASS dataset to construct a predictive model for treatment outcomes. Finally, prepare a comprehensive report that details the tumor’s immune profile and summarizes your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was profiled via a kidney biopsy and has a tumor mutational burden (TMB) of 5.0, what is the estimated likelihood of a positive clinical response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was profiled via a kidney biopsy and has a tumor mutational burden (TMB) of 5.0, what is the estimated likelihood of a positive clinical response to Atezolizumab therapy? Log into the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Begin by quantifying key immune cell populations—namely natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the patient’s immune response. Next, incorporate these measurements into the COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a detailed report that outlines the tumor’s immune profile and summarizes your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"For our white female patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is she to respond favorably to atezolizumab therapy?","For our white female patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is she to respond favorably to atezolizumab therapy? Please log into the COMPASS platform and initiate a transcriptomic analysis of the tumor microenvironment. Begin by quantifying key immune cell populations, including natural killer cells, exhausted T cells, B cells, and plasma cells, to evaluate the patient’s immune response. Next, integrate these quantified measurements into the COMPASS dataset to construct a predictive model for treatment outcomes. Finally, prepare a comprehensive report detailing the tumor’s immune profile along with a summary of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"For my WHITE F patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the expected likelihood of a positive response to atezolizumab therapy?","For my WHITE F patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the expected likelihood of a positive response to atezolizumab therapy? Please access the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Start by quantifying essential immune cell subsets such as natural killer cells, exhausted T cells, B cells, and plasma cells to assess the immune response. Then, incorporate these measurements into the COMPASS dataset to build a predictive model for treatment outcomes. Lastly, compile a detailed report that outlines the tumor’s immune profile along with a summary of your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"For my white male patient diagnosed with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a second biopsy, but the tumor mutational burden was not available. Based on this information, how likely is it that he would respond favorably to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a second biopsy, but the tumor mutational burden was not available. Based on this information, how likely is it that he would respond favorably to Atezolizumab therapy? Please log into the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Begin by quantifying key immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the immune response. Next, integrate these measurements into the COMPASS dataset to construct a predictive model for treatment outcomes. Finally, compile a comprehensive report detailing the tumor’s immune profile and summarizing your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"For my white female patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile from a lymph node biopsy detailing the tumor immune microenvironment. With a tumor mutation burden of 12, what are the chances of a positive response to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile from a lymph node biopsy detailing the tumor immune microenvironment. With a tumor mutation burden of 12, what are the chances of a positive response to Atezolizumab therapy? Please access the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Begin by quantifying essential immune cell populations—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the immune response. Then, incorporate these measurements into the COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a detailed report summarizing the tumor's immune profile and your key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"For my Asian male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 1.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my Asian male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 1.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Start by quantifying key immune cell populations—namely natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the immune response. Next, integrate these data into the COMPASS dataset to construct a predictive model for treatment outcomes. Finally, compile a comprehensive report that details the tumor's immune profile and highlights your main findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"For my white male patient with bladder urothelial carcinoma, the tumor biopsy transcriptomic profile of the immune microenvironment reveals a TMB of 6.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, the tumor biopsy transcriptomic profile of the immune microenvironment reveals a TMB of 6.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Please access the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Begin by quantifying key immune cell populations—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Then, integrate these quantitative data into the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a detailed report that outlines the tumor’s immune profile and summarizes your primary findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"For a female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment indicates a TMB of 8.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment indicates a TMB of 8.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Start by measuring the expression levels of key immune cells, including natural killer cells, exhausted T cells, B cells, and plasma cells, to assess the local immune response. Incorporate these measurements into the current COMPASS dataset to build a predictive model for treatment outcomes. Finally, generate a comprehensive report detailing the immune profile of the tumor and summarizing your main findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"For our Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutation burden (TMB) of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For our Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutation burden (TMB) of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Log in to the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Begin by quantifying the expression levels of key immune cell populations—namely natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Integrate these data into the current COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a detailed report that outlines the immune profile of the tumor and summarizes the primary findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma exhibiting a tumor mutational burden of 22.0 and a characterized transcriptomic profile of the tumor immune microenvironment, what is the expected likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma exhibiting a tumor mutational burden of 22.0 and a characterized transcriptomic profile of the tumor immune microenvironment, what is the expected likelihood of a favorable response to Atezolizumab therapy? Access the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. First, quantify the expression levels of critical immune cell types—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the local immune response. Then, integrate these measurements into the current COMPASS dataset to construct a predictive model for treatment outcomes. Finally, prepare a comprehensive report detailing the tumor's immune profile and summarizing the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 1.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 1.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to analyze the transcriptomic profile of the tumor microenvironment. Begin by quantifying the expression of key immune cell populations – natural killer cells, exhausted T cells, B cells, and plasma cells – to evaluate the local immune response. Next, incorporate these measurements into the existing COMPASS dataset to develop a model that predicts treatment outcomes. Conclude by generating a detailed report that outlines the tumor’s immune profile and summarizes the main findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"For my Caucasian patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, and the tumor mutational burden is reported as ""nan."" Based on these findings, how likely is it that the patient will respond positively to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, and the tumor mutational burden is reported as ""nan."" Based on these findings, how likely is it that the patient will respond positively to Atezolizumab therapy? Please use the COMPASS platform to analyze the transcriptomic profile of the tumor microenvironment. Begin by quantifying the expression of key immune cells, including natural killer cells, exhausted T cells, B cells, and plasma cells, to assess the local immune response. Then, integrate these data into the existing COMPASS dataset to build a predictive model for treatment outcomes. Finally, prepare a comprehensive report that details the tumor's immune profile and highlights the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 2.0, and whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 2.0, and whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, what is the likelihood of a favorable response to Atezolizumab therapy? Utilize the COMPASS platform to evaluate the tumor microenvironment's transcriptomic profile. Start by quantifying the expression levels of key immune cell populations—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to gauge the local immune response. Next, merge these findings with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a detailed report that outlines the tumor's immune characteristics and emphasizes the principal observations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"For our Caucasian patient diagnosed with bladder urothelial carcinoma, who has a transcriptomic profile of the tumor immune microenvironment obtained via bladder biopsy and a tumor mutational burden of 11.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For our Caucasian patient diagnosed with bladder urothelial carcinoma, who has a transcriptomic profile of the tumor immune microenvironment obtained via bladder biopsy and a tumor mutational burden of 11.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS platform to assess the transcriptomic profile of the tumor microenvironment. Begin by quantifying the expression of genes associated with key immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Then, integrate these results with the existing COMPASS dataset to build a predictive model for treatment outcomes. Finally, prepare a detailed report summarizing the immune features of the tumor and highlighting the most significant findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment via biopsy and has a tumor mutational burden of 9.0, how would you assess his likelihood of responding favorably to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment via biopsy and has a tumor mutational burden of 9.0, how would you assess his likelihood of responding favorably to atezolizumab therapy? Assess the tumor microenvironment’s transcriptomic profile using the COMPASS platform. Start by measuring the gene expression levels for key immune cells—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to determine the local immune response. Next, combine these results with the existing COMPASS data to develop a model that predicts treatment outcomes. Finally, compile a comprehensive report that details the tumor’s immune characteristics and emphasizes the most significant findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"For our Caucasian male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, although the tumor mutational burden is reported as not available. Given these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For our Caucasian male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, although the tumor mutational burden is reported as not available. Given these findings, what is the likelihood of a positive response to Atezolizumab therapy? Evaluate the tumor microenvironment’s gene expression profile using the COMPASS platform. Begin by measuring expression levels of key immune cell markers—including those for natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the local immune response. Then, integrate these findings with existing COMPASS data to develop a predictive model for treatment outcomes. Finally, prepare a detailed report that highlights the tumor’s immune characteristics and emphasizes the most critical insights.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"For my Caucasian patient with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor exhibits a TMB of 14.0. Based on these findings, how likely is the patient to respond positively to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor exhibits a TMB of 14.0. Based on these findings, how likely is the patient to respond positively to Atezolizumab therapy? Assess the tumor microenvironment's gene expression profile using the COMPASS platform. Start by quantifying key immune cell indicators, including markers for natural killer cells, exhausted T cells, B cells, and plasma cells, to evaluate the local immune response. Next, combine these results with existing COMPASS data to construct a predictive model for treatment outcomes. Finally, compile a comprehensive report that details the immune characteristics of the tumor and highlights the most significant findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"For my Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 18.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 18.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS platform to evaluate the gene expression profile within the tumor microenvironment. Begin by quantifying markers for key immune cell types—natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the local immune response. Then, integrate these findings with the existing COMPASS dataset to create a predictive model for treatment outcomes. Conclude the process by assembling a detailed report that describes the tumor's immune characteristics and emphasizes the most critical findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"For my white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile and a tumor mutation burden of 13.0 are available. Based on these data, what is the likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile and a tumor mutation burden of 13.0 are available. Based on these data, what is the likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to assess the gene expression profile in the tumor microenvironment. Start by quantifying markers for specific immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Next, integrate these measurements with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a comprehensive report detailing the immune characteristics of the tumor and highlighting the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"For a Black or African American female patient diagnosed with Bladder Urothelial Carcinoma, with a tumor mutational burden of 8.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a Black or African American female patient diagnosed with Bladder Urothelial Carcinoma, with a tumor mutational burden of 8.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS platform to evaluate the tumor microenvironment's gene expression profile. Begin by quantifying expression markers for immune cell types—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the local immune response. Then, merge these quantifications with the current COMPASS dataset to build a predictive model for treatment outcomes. Conclude by compiling a detailed report that outlines the tumor's immune characteristics and emphasizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"In a white female patient with bladder urothelial carcinoma, given that her tumor immune microenvironment transcriptomic profile and a tumor mutational burden (TMB) of 6.0 have been evaluated, what is the anticipated likelihood of a positive response to atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, given that her tumor immune microenvironment transcriptomic profile and a tumor mutational burden (TMB) of 6.0 have been evaluated, what is the anticipated likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to assess the gene expression profile of the tumor microenvironment. First, measure expression markers for immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Next, integrate these measurements with the existing COMPASS dataset to construct a predictive model for treatment outcomes. Finally, prepare a comprehensive report summarizing the immune characteristics of the tumor and highlight the principal findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, and his reported tumor mutational burden is 'nan.' Based on these findings, what is the likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, and his reported tumor mutational burden is 'nan.' Based on these findings, what is the likelihood of a positive response to atezolizumab therapy? Use the COMPASS platform to evaluate the gene expression profile of the tumor microenvironment. Begin by quantifying expression markers for immune cells—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the local immune response. Then, merge these data with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a detailed report that summarizes the immune characteristics of the tumor and highlights the main findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone a bladder biopsy yielding transcriptomic profiling of the tumor immune microenvironment and exhibits a TMB of 23.0, how would you assess the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone a bladder biopsy yielding transcriptomic profiling of the tumor immune microenvironment and exhibits a TMB of 23.0, how would you assess the likelihood of a positive response to Atezolizumab therapy? Please utilize the COMPASS platform to analyze the gene expression profile within the tumor microenvironment. Begin by quantifying the expression of immune cell markers—including those for natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Next, incorporate these measurements with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a comprehensive report that details the immune characteristics of the tumor and emphasizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"For a Caucasian female patient with bladder urothelial carcinoma (BLCA) whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment and with a tumor mutation burden (TMB) reported as not available, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma (BLCA) whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment and with a tumor mutation burden (TMB) reported as not available, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to evaluate gene expression profiles within the tumor microenvironment. Start by quantifying immune cell markers—including those for natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the local immune response. Next, integrate these measurements with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, generate a detailed report outlining the immune characteristics of the tumor and emphasizing the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor immune microenvironment transcriptomic profile from a lymph node biopsy and a tumor mutational burden of 2.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor immune microenvironment transcriptomic profile from a lymph node biopsy and a tumor mutational burden of 2.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to analyze gene expression profiles in the tumor microenvironment. Begin by quantifying markers for key immune cells—specifically, natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Then, integrate these results with the existing COMPASS dataset to build a predictive model for treatment outcomes. Finally, prepare a comprehensive report that details the immune characteristics of the tumor and highlights the most significant findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) was reported as ""nan."" Given these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) was reported as ""nan."" Given these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to evaluate gene expression profiles within the tumor microenvironment. Start by measuring markers for specific immune cells—namely, natural killer cells, exhausted T cells, B cells, and plasma cells—in order to assess the local immune response. Next, combine these findings with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a detailed report that outlines the immune characteristics of the tumor and emphasizes the most significant findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"In a white male patient with bladder urothelial carcinoma who exhibits a tumor mutational burden of 7.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who exhibits a tumor mutational burden of 7.0 and for whom we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to assess gene expression profiles in the tumor microenvironment. Begin by measuring markers for specific immune cell populations—namely natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Next, integrate these results with the existing COMPASS dataset to construct a predictive model for treatment outcomes. Finally, compile a comprehensive report that details the immune characteristics of the tumor and highlights the most significant findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"For an Asian male patient with bladder urothelial carcinoma who has a tumor microenvironment transcriptomic profile from a bladder biopsy and a tumor mutational burden of 1.0, what is the likelihood of achieving a positive response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma who has a tumor microenvironment transcriptomic profile from a bladder biopsy and a tumor mutational burden of 1.0, what is the likelihood of achieving a positive response to Atezolizumab therapy? Use the COMPASS platform to analyze gene expression within the tumor microenvironment. Start by quantifying markers for immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the local immune response. Then, merge these findings with the current COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a detailed report that outlines the immune characteristics of the tumor and emphasizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"For my Caucasian male patient with a diagnosis of bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy was performed, and the tumor mutational burden is 7.0. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy?","For my Caucasian male patient with a diagnosis of bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy was performed, and the tumor mutational burden is 7.0. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy? Utilize the COMPASS platform to evaluate gene expression in the tumor microenvironment. Begin by quantifying markers for immune cell populations, including natural killer cells, exhausted T cells, B cells, and plasma cells, to assess the local immune response. Next, integrate these results with the current COMPASS dataset to construct a predictive model for treatment outcomes. Finally, compile a comprehensive report that details the immune characteristics of the tumor and highlights the principal findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy indicates a tumor mutation burden of 5.0, what is the anticipated likelihood of a positive response to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy indicates a tumor mutation burden of 5.0, what is the anticipated likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to analyze gene expression within the tumor microenvironment. First, quantify markers for specific immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Then, combine these results with the existing COMPASS dataset to build a predictive model for treatment outcomes. Finally, prepare a detailed report that summarizes the immune characteristics of the tumor and highlights the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 6.0, what is the anticipated response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 6.0, what is the anticipated response to Atezolizumab therapy? Utilize the COMPASS platform to assess gene expression within the tumor microenvironment. Begin by quantifying markers for selected immune cell populations—namely, natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Next, integrate these measurements with the current COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a comprehensive report detailing the immune attributes of the tumor and emphasizing the primary findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"For my Caucasian patient with bladder urothelial carcinoma, for whom I obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy and a tumor mutational burden (TMB) recorded as ""nan,"" what is the likelihood of a positive response to atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, for whom I obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy and a tumor mutational burden (TMB) recorded as ""nan,"" what is the likelihood of a positive response to atezolizumab therapy? Please employ the COMPASS platform to evaluate gene expression profiles within the tumor microenvironment. Begin by quantifying the markers associated with specific immune cell populations, including natural killer cells, exhausted T cells, B cells, and plasma cells, to assess the local immune response. Then, merge these findings with the existing COMPASS dataset to construct a predictive model for treatment outcomes. Finally, prepare a detailed report that outlines the immune characteristics of the tumor and emphasizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma who has a lymph node biopsy transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden (TMB) of 2.0, what is the likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma who has a lymph node biopsy transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden (TMB) of 2.0, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to analyze gene expression profiles in the tumor microenvironment. Start by quantifying markers for specific immune cell populations—namely natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Next, integrate these data with the current COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a comprehensive report detailing the immune characteristics of the tumor and highlighting the major findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"For my Caucasian male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy shows a tumor mutational burden of 44.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy shows a tumor mutational burden of 44.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please utilize the COMPASS platform to conduct an analysis of gene expression profiles within the tumor microenvironment. Begin by quantifying markers for key immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the local immune response. Then, combine these data with the existing COMPASS dataset to construct a predictive model for treatment outcomes. Finally, compile a detailed report that summarizes the tumor’s immune characteristics and highlights the principal findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 15.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 15.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to analyze the gene expression profiles within the tumor microenvironment. First, quantify the expression markers for major immune cell populations—namely, natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Next, integrate these results with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, generate a comprehensive report that details the tumor’s immune characteristics and summarizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 17, based on the transcriptomic profile of the tumor immune microenvironment obtained from a lymph node biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 17, based on the transcriptomic profile of the tumor immune microenvironment obtained from a lymph node biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to assess gene expression within the tumor microenvironment. Begin by quantifying the expression markers for key immune cell populations—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—to gauge the local immune response. Then, integrate these findings with the existing COMPASS dataset to build a predictive model for treatment outcomes. Lastly, compile a detailed report outlining the tumor’s immune profile and summarizing the main findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"I am evaluating a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0. Transcriptomic profiling of the tumor immune microenvironment was obtained from a kidney biopsy. Based on these findings, what is the estimated likelihood that he will respond positively to atezolizumab therapy?","I am evaluating a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0. Transcriptomic profiling of the tumor immune microenvironment was obtained from a kidney biopsy. Based on these findings, what is the estimated likelihood that he will respond positively to atezolizumab therapy? Utilize the COMPASS platform to evaluate gene expression within the tumor microenvironment. Start by quantifying the expression markers associated with critical immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the local immune response. Next, merge these results with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a comprehensive report that details the tumor’s immune profile and summarizes the primary findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"For a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was obtained from a bladder biopsy, and the tumor mutational burden (TMB) is currently not available. Based on these data, how likely is the patient to respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was obtained from a bladder biopsy, and the tumor mutational burden (TMB) is currently not available. Based on these data, how likely is the patient to respond favorably to Atezolizumab therapy? Please use the COMPASS platform to assess gene expression in the tumor microenvironment. Begin by quantifying expression markers for key immune cells—namely natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Then, combine these measurements with your current COMPASS dataset to create a predictive model for treatment outcomes. Finally, compile a detailed report that outlines the tumor’s immune profile and summarizes the main results.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy—and with the tumor mutational burden (TMB) reported as not available—what is the expected likelihood of a favorable therapeutic response to Atezolizumab?,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy—and with the tumor mutational burden (TMB) reported as not available—what is the expected likelihood of a favorable therapeutic response to Atezolizumab? Please use the COMPASS platform to evaluate gene expression within the tumor microenvironment. Start by quantifying markers that specifically identify critical immune cells, including natural killer cells, exhausted T cells, B cells, and plasma cells, to assess the local immune response. Next, integrate these measurements with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Lastly, prepare a comprehensive report summarizing the tumor’s immune profile and outlining the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"For my white male patient with bladder urothelial carcinoma, I obtained transcriptomic profiling data from a bladder biopsy that indicates a tumor mutational burden of 12.0. Based on these findings, what is the expected likelihood of a favorable response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained transcriptomic profiling data from a bladder biopsy that indicates a tumor mutational burden of 12.0. Based on these findings, what is the expected likelihood of a favorable response to atezolizumab therapy? Please use the COMPASS platform to analyze gene expression in the tumor microenvironment. Begin by quantifying markers for key immune cells—such as natural killer cells, exhausted T cells, B cells, and plasma cells—to evaluate the local immune response. Then, combine these measurements with the existing COMPASS dataset to build a predictive model for treatment outcomes. Finally, generate a detailed report that summarizes the tumor’s immune profile and highlights the main findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"For my white male patient with bladder urothelial carcinoma, the transcriptomic profiling of the tumor immune microenvironment from his bladder biopsy shows a tumor mutational burden of 6.0. Based on these findings, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, the transcriptomic profiling of the tumor immune microenvironment from his bladder biopsy shows a tumor mutational burden of 6.0. Based on these findings, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to assess gene expression within the tumor microenvironment. Start by quantifying markers associated with critical immune cell populations—such as natural killer cells, exhausted T cells, B cells, and plasma cells—to gauge the local immune response. Next, integrate these results with the existing COMPASS dataset to develop a model that predicts treatment outcomes. Finally, compile a comprehensive report that details the tumor’s immune profile and summarizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"For a Caucasian male patient with a diagnosis of bladder urothelial carcinoma, who has undergone transcriptomic profiling of the tumor immune microenvironment via bladder biopsy and presents with a tumor mutational burden (TMB) of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with a diagnosis of bladder urothelial carcinoma, who has undergone transcriptomic profiling of the tumor immune microenvironment via bladder biopsy and presents with a tumor mutational burden (TMB) of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please utilize the COMPASS platform to evaluate gene expression within the tumor microenvironment. Begin by quantifying markers for key immune cell populations—including natural killer cells, exhausted T cells, B cells, and plasma cells—to assess the local immune response. Next, integrate these findings with the existing COMPASS dataset to construct a predictive model for treatment outcomes. Conclude by preparing a detailed report that outlines the tumor’s immune profile and highlights the primary discoveries.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"For my white male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained via nano biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained via nano biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to analyze gene expression within the tumor microenvironment. Begin by quantifying markers for key immune cell types—namely natural killer cells, exhausted T cells, B cells, and plasma cells—to determine the local immune response. Then, merge these data with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a detailed report that outlines the immune profile of the tumor and summarizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"For a White patient diagnosed with bladder urothelial carcinoma (BLCA) with a tumor mutation burden (TMB) of 8.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For a White patient diagnosed with bladder urothelial carcinoma (BLCA) with a tumor mutation burden (TMB) of 8.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to atezolizumab therapy? Utilize the COMPASS platform to assess gene expression in the tumor microenvironment by quantifying markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Next, integrate these measurements with the existing COMPASS dataset to build a predictive model for treatment outcomes. Finally, compile a detailed report that outlines the immune profile of the tumor and highlights the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"In a patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized by transcriptomic profiling from a bladder biopsy and who has a tumor mutational burden (TMB) of 0.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma whose tumor immune microenvironment was characterized by transcriptomic profiling from a bladder biopsy and who has a tumor mutational burden (TMB) of 0.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to evaluate gene expression within the tumor microenvironment, focusing on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these data with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a detailed report that describes the tumor’s immune profile and emphasizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 5.0, based on transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 5.0, based on transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Utilize the COMPASS platform to assess gene expression within the tumor microenvironment, with particular attention to markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Next, merge these data with the current COMPASS dataset to build a predictive model for treatment outcomes. Finally, compile a comprehensive report detailing the tumor’s immune profile, highlighting the critical findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"For a Caucasian patient with bladder urothelial carcinoma who has a tumor mutation burden of 6.0 and for whom transcriptomic profiling of the tumor immune microenvironment was performed using a kidney biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma who has a tumor mutation burden of 6.0 and for whom transcriptomic profiling of the tumor immune microenvironment was performed using a kidney biopsy, what is the likelihood of a favorable response to atezolizumab therapy? Please use the COMPASS platform to evaluate gene expression in the tumor microenvironment, focusing specifically on markers associated with natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have obtained these data, integrate them with the existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a detailed report summarizing the tumor’s immune profile, emphasizing the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"I have a white female patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic profiling of the tumor immune microenvironment. However, her tumor mutation burden is not available. Based on these findings, what is the expected likelihood of a positive response to atezolizumab therapy?","I have a white female patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic profiling of the tumor immune microenvironment. However, her tumor mutation burden is not available. Based on these findings, what is the expected likelihood of a positive response to atezolizumab therapy? Utilize the COMPASS platform to assess gene expression within the tumor microenvironment, paying particular attention to markers for natural killer cells, exhausted T cells, B cells, and plasma cells. After obtaining these data, merge them with the existing COMPASS dataset to construct a predictive model for treatment outcomes. Finally, compile a comprehensive report detailing the tumor’s immune profile and highlighting the significant findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"For a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 59 and a transcriptomic profile of the tumor immune microenvironment derived from a ureter biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 59 and a transcriptomic profile of the tumor immune microenvironment derived from a ureter biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to evaluate gene expression in the tumor microenvironment, focusing on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have these data, combine them with our current COMPASS dataset to develop a predictive model for treatment outcomes. Finally, generate a detailed report that summarizes the tumor's immune profile and highlights the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden measures 13.0. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden measures 13.0. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy? Please utilize the COMPASS platform to assess gene expression within the tumor microenvironment, concentrating on markers related to natural killer cells, exhausted T cells, B cells, and plasma cells. After obtaining this data, merge it with our existing COMPASS dataset to build a predictive model for treatment outcomes. Finally, compile a comprehensive report that details the tumor's immune profile and underscores the significant findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 12.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a ureter biopsy, what is the likelihood of a positive response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 12.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a ureter biopsy, what is the likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to evaluate gene expression in the tumor microenvironment, specifically focusing on markers associated with natural killer cells, exhausted T cells, B cells, and plasma cells. Following this analysis, integrate the new gene expression data with our current COMPASS dataset to develop a predictive model for treatment outcomes. Lastly, prepare a detailed report summarizing the tumor's immune profile and highlighting the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling from a lymph node biopsy revealed a tumor mutational burden of 4.0. Based on these findings, what is the projected likelihood of a positive response to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling from a lymph node biopsy revealed a tumor mutational burden of 4.0. Based on these findings, what is the projected likelihood of a positive response to atezolizumab therapy? Please utilize the COMPASS platform to assess gene expression within the tumor microenvironment, with a particular focus on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once this analysis is complete, combine the new gene expression data with our existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a comprehensive report detailing the tumor's immune profile and emphasizing the critical findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"For our white male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden was measured at 11.0. What is the estimated likelihood of this patient responding favorably to Atezolizumab therapy?","For our white male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden was measured at 11.0. What is the estimated likelihood of this patient responding favorably to Atezolizumab therapy? Please use the COMPASS platform to analyze gene expression in the tumor microenvironment, focusing specifically on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, integrate these new data with our existing COMPASS dataset to build a predictive model for treatment outcomes. Lastly, prepare a detailed report that presents the tumor’s immune profile and highlights the critical findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy? Please utilize the COMPASS platform to conduct a gene expression analysis within the tumor microenvironment. Your focus should be on evaluating markers associated with natural killer cells, exhausted T cells, B cells, and plasma cells. After finalizing the analysis, merge these new findings with our current COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a comprehensive report detailing the tumor’s immune profile and emphasizing the key observations.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"For my Caucasian female patient with bladder urothelial carcinoma, a kidney biopsy yielded a transcriptomic profile of the tumor immune microenvironment with a reported tumor mutational burden (TMB) value of ""nan."" Based on these parameters, what is the likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, a kidney biopsy yielded a transcriptomic profile of the tumor immune microenvironment with a reported tumor mutational burden (TMB) value of ""nan."" Based on these parameters, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a gene expression analysis that focuses on the tumor microenvironment. Specifically, assess markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have completed the analysis, integrate these data with our existing COMPASS dataset to build a predictive model for treatment outcomes. Finally, prepare a detailed report that outlines the tumor’s immune profile and highlights the most important findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a gene expression analysis that targets the tumor microenvironment. Focus specifically on evaluating expression markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Upon completion, integrate these findings with our existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a detailed report that summarizes the tumor’s immune profile and emphasizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"For a Native Hawaiian or other Pacific Islander patient with bladder urothelial carcinoma who has a tumor mutational burden of 19.0, and whose tumor immune microenvironment was profiled via transcriptomic analysis from a biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a Native Hawaiian or other Pacific Islander patient with bladder urothelial carcinoma who has a tumor mutational burden of 19.0, and whose tumor immune microenvironment was profiled via transcriptomic analysis from a biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy? Using the COMPASS platform, please perform a gene expression analysis focused on the tumor microenvironment. Specifically, assess the expression markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, merge these data with our current COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a comprehensive report detailing the tumor’s immune profile and highlighting the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"For my white male patient with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. With the tumor mutation burden unavailable, what can we infer about his likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. With the tumor mutation burden unavailable, what can we infer about his likelihood of a positive response to Atezolizumab therapy? Please perform a gene expression analysis on the tumor microenvironment using our COMPASS platform. Focus on evaluating markers for natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, integrate the results with our existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a detailed report that outlines the tumor’s immune profile and highlights the principal findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-563d62-ar-563d623.pkl. "
BLCA,,,,NR,"For my White female patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile obtained from a bladder biopsy indicates a TMB value reported as ""nan."" Based on these data, what is the evidence-based likelihood of a positive response to Atezolizumab therapy?","For my White female patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile obtained from a bladder biopsy indicates a TMB value reported as ""nan."" Based on these data, what is the evidence-based likelihood of a positive response to Atezolizumab therapy? Please use our COMPASS platform to conduct a gene expression analysis of the tumor microenvironment. Specifically, evaluate markers related to natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, merge these new results with our current COMPASS dataset to construct a predictive model for treatment outcomes. Finally, prepare a comprehensive report detailing the tumor's immune profile and outlining the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and his tumor mutational burden is 33.0. Based on these factors, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and his tumor mutational burden is 33.0. Based on these factors, what is the estimated likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to perform a gene expression analysis of the tumor microenvironment. In your analysis, focus on markers associated with natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have completed the analysis, integrate the new results with our existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a detailed report that outlines the tumor's immune profile and summarizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"For my White male patient with bladder urothelial carcinoma, who has undergone transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden of 32, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For my White male patient with bladder urothelial carcinoma, who has undergone transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden of 32, what is the estimated likelihood of a favorable response to atezolizumab therapy? Please use the COMPASS system to conduct a gene expression analysis of the tumor microenvironment, specifically targeting markers for natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, integrate your new findings with our current COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a comprehensive report that details the tumor's immune profile and highlights the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"For a white male patient with bladder urothelial carcinoma, how would you assess the likelihood of a positive response to Atezolizumab given the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutation burden of 2.0?","For a white male patient with bladder urothelial carcinoma, how would you assess the likelihood of a positive response to Atezolizumab given the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutation burden of 2.0? Please use the COMPASS system to analyze gene expression within the tumor microenvironment, focusing on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, integrate these new data with our existing COMPASS dataset to build a predictive model for treatment outcomes. Finally, compile a detailed report outlining the tumor's immune profile and emphasizing the main findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and a transcriptomic profile detailing the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and a transcriptomic profile detailing the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to evaluate gene expression in the tumor microenvironment with a focus on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, merge these results with our current COMPASS dataset to create a predictive model for treatment outcomes. Finally, prepare a detailed report that summarizes the tumor's immune profile and highlights the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"For my white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled using transcriptomic analysis from a nano-biopsy and who exhibits a tumor mutational burden (TMB) value of nan, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled using transcriptomic analysis from a nano-biopsy and who exhibits a tumor mutational burden (TMB) value of nan, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to assess gene expression within the tumor microenvironment, specifically targeting markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have completed this analysis, integrate the findings with our existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a comprehensive report that details the tumor’s immune profile and emphasizes the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"For my Caucasian male patient with bladder urothelial carcinoma, the tumor biopsy reveals a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 9.0 mutations per megabase. Based on these findings, how likely is he to experience a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, the tumor biopsy reveals a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 9.0 mutations per megabase. Based on these findings, how likely is he to experience a favorable response to Atezolizumab therapy? Please use the COMPASS system to evaluate gene expression within the tumor microenvironment, focusing on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. After completing this analysis, merge your results with our existing COMPASS dataset to construct a predictive model for treatment outcomes. Finally, prepare a detailed report that outlines the tumor’s immune profile and highlights the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"For an Asian female patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy and a tumor mutation burden (TMB) of 12, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For an Asian female patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy and a tumor mutation burden (TMB) of 12, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to assess gene expression in the tumor microenvironment, specifically analyzing markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once this analysis is complete, integrate your findings with our existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, compile a comprehensive report detailing the tumor’s immune profile and emphasizing the most significant findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"For a white male patient with biopsy-confirmed bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment indicates a TMB value of 'nan', what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with biopsy-confirmed bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment indicates a TMB value of 'nan', what is the likelihood of a favorable response to Atezolizumab therapy? Please utilize the COMPASS system to evaluate gene expression within the tumor microenvironment, focusing on markers that indicate the presence of natural killer cells, exhausted T cells, B cells, and plasma cells. After completing this assessment, merge your results with our current COMPASS dataset to construct a predictive model for treatment outcomes. Finally, generate a detailed report that outlines the tumor's immune profile and highlights the key findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"For my white male patient with bladder urothelial carcinoma, whose tumor transcriptomic profile of the immune microenvironment shows a TMB of 11.0, what is the likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose tumor transcriptomic profile of the immune microenvironment shows a TMB of 11.0, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to analyze gene expression in the tumor microenvironment, specifically evaluating markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have completed this evaluation, integrate your findings with our existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a comprehensive report detailing the tumor's immune profile and emphasizing the most significant findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA), a tumor mutation burden (TMB) of 10.0, and a transcriptomic profile of the tumor immune microenvironment obtained from a liver biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), a tumor mutation burden (TMB) of 10.0, and a transcriptomic profile of the tumor immune microenvironment obtained from a liver biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to assess gene expression within the tumor microenvironment. Your analysis should focus on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, integrate these results with our existing COMPASS dataset to build a predictive model for treatment outcomes. Finally, compile a detailed report that outlines the tumor's immune profile, emphasizing the key findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile shows specific tumor immune microenvironment characteristics and a tumor mutational burden of 12.0, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile shows specific tumor immune microenvironment characteristics and a tumor mutational burden of 12.0, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to evaluate gene expression in the tumor microenvironment. Concentrate on quantifying markers related to natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have completed the analysis, merge these findings with our current COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a comprehensive report detailing the tumor's immune profile, highlighting the most significant observations from your assessment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"For my patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reveals a TMB of 13.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reveals a TMB of 13.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS system to assess gene expression within the tumor microenvironment, focusing specifically on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once this analysis is complete, integrate your findings with our existing COMPASS dataset to construct a predictive model for treatment outcomes. Finally, compile a comprehensive report that details the tumor's immune profile and highlights the most critical findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"For my Caucasian patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 6.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden (TMB) of 6.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to analyze gene expression within the tumor microenvironment, specifically targeting markers for natural killer cells, exhausted T cells, B cells, and plasma cells. After completing this analysis, merge your results with our existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a detailed report that outlines the tumor’s immune profile and emphasizes the most critical findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"For my White patient with Bladder Urothelial Carcinoma, whose tumor immune microenvironment was profiled via ureter biopsy and who has a tumor mutational burden of 21.0, what is the likelihood of achieving a positive response to Atezolizumab therapy?","For my White patient with Bladder Urothelial Carcinoma, whose tumor immune microenvironment was profiled via ureter biopsy and who has a tumor mutational burden of 21.0, what is the likelihood of achieving a positive response to Atezolizumab therapy? Utilize the COMPASS system to assess gene expression within the tumor microenvironment, focusing on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, integrate these new findings with our current COMPASS dataset to construct a predictive model for treatment outcomes. Finally, develop a comprehensive report that clearly outlines the tumor's immune profile and emphasizes the key findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"For my Caucasian male patient with bladder urothelial carcinoma, the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutation burden of 14.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, the transcriptomic profile of his tumor immune microenvironment from a bladder biopsy indicates a tumor mutation burden of 14.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS system to analyze gene expression within the tumor microenvironment, specifically evaluating markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, incorporate these findings into our existing COMPASS dataset to develop a predictive model for treatment outcomes. Finally, prepare a detailed report that outlines the tumor's immune profile and highlights the most important results of your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is 9.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is 9.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS system to assess gene expression in the tumor microenvironment, focusing on markers for natural killer cells, exhausted T cells, B cells, and plasma cells. After completing this assessment, integrate your results into our existing COMPASS dataset so that we can develop a predictive model for treatment outcomes. Finally, generate a detailed report that outlines the tumor's immune profile and identifies the key findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 27.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 27.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS system to analyze gene expression related to natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you have completed this evaluation, add your findings to the existing COMPASS dataset to facilitate the development of a predictive model for treatment outcomes. Finally, prepare a detailed report that summarizes the immune profile of the tumor and highlights the key results from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"For our white female patient diagnosed with bladder urothelial carcinoma (BLCA), where a transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy has been performed and the tumor mutational burden (TMB) value is not specified, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For our white female patient diagnosed with bladder urothelial carcinoma (BLCA), where a transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy has been performed and the tumor mutational burden (TMB) value is not specified, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please analyze gene expression profiles for natural killer cells, exhausted T cells, B cells, and plasma cells in the tumor microenvironment using the COMPASS system. After completing this assessment, integrate your findings into the current COMPASS dataset to support the development of a predictive model for treatment outcomes. Finally, compile a comprehensive report that details the tumor's immune profile and emphasizes the key findings of your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"For a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a kidney biopsy and found to have a tumor mutational burden of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via a kidney biopsy and found to have a tumor mutational burden of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS system to evaluate gene expression in natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you have completed this evaluation, integrate the results into the existing COMPASS dataset to assist in developing a predictive model for treatment outcomes. Finally, prepare a detailed report summarizing the tumor’s immune profile and emphasizing the key findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment was performed on a bladder biopsy, and the tumor mutation burden (TMB) is reported as nan. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment was performed on a bladder biopsy, and the tumor mutation burden (TMB) is reported as nan. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Using the COMPASS system, please assess gene expression in natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing this evaluation, integrate your findings into the current COMPASS dataset to support the development of a treatment outcome predictive model. Finally, compile a detailed report of the tumor's immune profile, highlighting the key results from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"For a White male patient with bladder urothelial carcinoma, we've obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 14.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma, we've obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 14.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS system to evaluate gene expression in natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once completed, integrate these results into the existing COMPASS dataset to help build a model that predicts treatment outcomes. Finally, prepare a comprehensive report detailing the tumor's immune profile and emphasizing the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 4.0. Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 4.0. Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy? Please use the COMPASS system to assess gene expression in natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing the analysis, incorporate the data into the existing COMPASS dataset to help develop a model that predicts treatment outcomes. Finally, prepare a detailed report that outlines the tumor’s immune profile and highlights the most important findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"For my white patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 5.0 and a detailed transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 5.0 and a detailed transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS system to evaluate gene expression profiles in natural killer cells, exhausted T cells, B cells, and plasma cells located in the tumor microenvironment. Once you have completed the analysis, integrate these findings into our existing COMPASS dataset to support the development of a predictive treatment outcome model. Finally, compile a comprehensive report detailing the immune profile of the tumor, emphasizing the key observations from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"For a white female patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden of 15.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden of 15.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to analyze gene expression profiles in natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing this analysis, integrate your results into our existing COMPASS dataset to aid in developing a predictive model for treatment outcomes. Finally, prepare a detailed report summarizing the tumor’s immune profile, highlighting the most significant findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 13.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 13.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Utilize the COMPASS system to assess the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells in the tumor microenvironment. Once you have completed this analysis, integrate the data into our existing COMPASS dataset to support the development of a predictive model for treatment outcomes. Finally, compile a comprehensive report that summarizes the tumor’s immune profile and emphasizes the most significant findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"For a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 14.0 and specific transcriptomic data from the tumor immune microenvironment, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 14.0 and specific transcriptomic data from the tumor immune microenvironment, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS system to evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells in the tumor microenvironment. After completing this analysis, merge the findings with our current COMPASS dataset to enhance our predictive model for treatment outcomes. Finally, prepare a detailed report summarizing the tumor's immune profile, with an emphasis on the most significant results from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"For my Black/African American male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor's immune microenvironment reveals a tumor mutational burden of 17.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my Black/African American male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor's immune microenvironment reveals a tumor mutational burden of 17.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once this evaluation is complete, integrate these findings with our existing COMPASS dataset to refine our predictive model for treatment responses. Finally, compile a comprehensive report that details the tumor's immune profile, highlighting the most critical outcomes of your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"For my white male patient with bladder urothelial carcinoma, whose biopsy transcriptomic analysis reveals a tumor mutational burden of 7.0, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose biopsy transcriptomic analysis reveals a tumor mutational burden of 7.0, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please use the COMPASS system to evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells found within the tumor microenvironment. After completing the analysis, integrate these results with our current COMPASS dataset to update our predictive model for treatment responses. Finally, prepare a detailed report summarizing the immune profile of the tumor, with a focus on the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy reveals a tumor mutational burden (TMB) of 5.0, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy reveals a tumor mutational burden (TMB) of 5.0, what is the likelihood of a positive response to Atezolizumab therapy? Use the COMPASS platform to assess the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once the analysis is complete, merge these data with our existing COMPASS dataset to refine our predictive model for treatment responses. Finally, compile a comprehensive report that highlights the key immune characteristics of the tumor, emphasizing the most critical findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"For my white male patient with bladder urothelial carcinoma and a tumor mutation burden of 20.0, based on the transcriptomic profiling of the tumor immune microenvironment from his lung biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma and a tumor mutation burden of 20.0, based on the transcriptomic profiling of the tumor immune microenvironment from his lung biopsy, what is the likelihood of a favorable response to atezolizumab therapy? Please use the COMPASS platform to evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you have completed the analysis, integrate these results with our existing COMPASS dataset to update our predictive model for treatment responses. Finally, prepare a detailed report that summarizes the key immune characteristics of the tumor, clearly emphasizing the most significant findings from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile reveals a TMB of 3.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile reveals a TMB of 3.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS platform to analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells in the tumor microenvironment. After completing the analysis, integrate these results with our existing COMPASS dataset to update our predictive model for treatment responses. Finally, prepare a detailed report outlining the key immune characteristics of the tumor, highlighting the most significant findings from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"For my Black or African American patient with bladder urothelial carcinoma (BLCA), we have a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy and an indeterminate tumor mutational burden. Based on these findings, how likely is a favorable response to Atezolizumab therapy?","For my Black or African American patient with bladder urothelial carcinoma (BLCA), we have a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy and an indeterminate tumor mutational burden. Based on these findings, how likely is a favorable response to Atezolizumab therapy? Please use the COMPASS platform to evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once the analysis is complete, merge these new data with our current COMPASS dataset to refine the predictive model for treatment responses. Lastly, compile a detailed report that summarizes the key immune characteristics of the tumor and emphasizes the most significant findings from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been performed and the TMB value is unavailable, what is the likelihood of a positive response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been performed and the TMB value is unavailable, what is the likelihood of a positive response to atezolizumab therapy? Use the COMPASS platform to assess the gene expression profiles of the natural killer cells, exhausted T cells, B cells, and plasma cells present in the tumor microenvironment. After completing the analysis, integrate the new data with our existing COMPASS dataset to enhance our predictive model for treatment responses. Finally, prepare a comprehensive report that outlines the key immune features of the tumor and highlights the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"For our white female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment via nanobiopsy revealed a tumor mutation burden of 8.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For our white female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment via nanobiopsy revealed a tumor mutation burden of 8.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells from the tumor microenvironment. After you complete the analysis, integrate these new data with our existing COMPASS dataset to improve our predictive model for treatment responses. Finally, compile a detailed report that summarizes the main immune characteristics of the tumor and highlights the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is 6.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is 6.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please perform an analysis of the gene expression profiles for natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment using the COMPASS platform. Once the analysis is complete, integrate the newly obtained data with our existing COMPASS dataset to refine our predictive model for treatment responses. Finally, prepare a comprehensive report that details the principal immune characteristics of the tumor and emphasizes the most noteworthy findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"For my Caucasian male patient with bladder urothelial carcinoma, whose tumor biopsy transcriptomic profile of the immune microenvironment and a tumor mutation burden of 17.0 have been obtained, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, whose tumor biopsy transcriptomic profile of the immune microenvironment and a tumor mutation burden of 17.0 have been obtained, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells in the tumor microenvironment. After completing this analysis, integrate the new data with our current COMPASS dataset to enhance our predictive model for treatment responses. Finally, compile a detailed report that outlines the key immunological features of the tumor and emphasizes the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA), whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 6.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA), whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 6.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment using the COMPASS platform. Once this analysis is complete, integrate these results with our existing COMPASS dataset to refine our predictive model for treatment responses. Finally, prepare a comprehensive report detailing the key immunological characteristics of the tumor, with a particular focus on the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"For my Caucasian patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, and the tumor mutational burden is 1.0. Based on these factors, what is the predicted likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, and the tumor mutational burden is 1.0. Based on these factors, what is the predicted likelihood of a positive response to Atezolizumab therapy? Please evaluate the gene expression patterns of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment using the COMPASS platform. After completing this analysis, merge your findings with our existing COMPASS dataset to update our predictive model for treatment responses. Lastly, compile a detailed report that outlines the key immunological features of the tumor, emphasizing the most significant results derived from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"For a white male patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic analysis of the tumor immune microenvironment, and whose tumor mutational burden is reported as nan, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic analysis of the tumor immune microenvironment, and whose tumor mutational burden is reported as nan, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells present in the tumor microenvironment using the COMPASS platform. Once completed, integrate your results into our current COMPASS dataset to refine our predictive model for treatment responses. Finally, prepare a comprehensive report that details the key immunological characteristics of the tumor and highlights the most critical findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"In a white female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 7.0 mutations per megabase. Based on these findings, what is the estimated likelihood of her responding favorably to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 7.0 mutations per megabase. Based on these findings, what is the estimated likelihood of her responding favorably to Atezolizumab therapy? Please evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells in the tumor microenvironment using the COMPASS platform. After completing your analysis, integrate your results with our existing COMPASS dataset to enhance our predictive model for treatment responses. Lastly, prepare a detailed report that outlines the key immunological characteristics of the tumor and emphasizes the most significant findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"For my white female patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and her tumor has a mutational burden of 21. Based on this information, what is the likelihood of a positive response to atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and her tumor has a mutational burden of 21. Based on this information, what is the likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once your analysis is complete, merge these findings with our current COMPASS dataset to improve our predictive model of treatment responses. Finally, compile a comprehensive report detailing the key immunological features of the tumor and highlighting the most significant results from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"For my white male patient with bladder urothelial carcinoma, a ureter biopsy revealed transcriptomic profiling of the tumor immune microenvironment and a TMB of 7.0. Given these findings, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a ureter biopsy revealed transcriptomic profiling of the tumor immune microenvironment and a TMB of 7.0. Given these findings, what is the estimated likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells present in the tumor microenvironment. After completing this analysis, integrate the new data with our existing COMPASS dataset to refine our predictive model for treatment responses. Finally, prepare a detailed report that outlines the key immunological characteristics of the tumor and emphasizes the most significant findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma, where a transcriptomic analysis of the tumor immune microenvironment was performed on a lung biopsy and the tumor mutational burden is 6.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, where a transcriptomic analysis of the tumor immune microenvironment was performed on a lung biopsy and the tumor mutational burden is 6.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Using the COMPASS platform, please assess the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you've completed this evaluation, integrate these new data into our current COMPASS dataset to update and refine our treatment response predictive model. Finally, generate a comprehensive report that details the tumor's key immunological features, highlighting the most notable findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was evaluated via kidney biopsy and who exhibits a tumor mutational burden of 6.0, what is the likelihood of a positive therapeutic response to atezolizumab?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was evaluated via kidney biopsy and who exhibits a tumor mutational burden of 6.0, what is the likelihood of a positive therapeutic response to atezolizumab? Please use the COMPASS platform to evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells present in the tumor microenvironment. After completing the analysis, incorporate these findings into our existing COMPASS dataset to update and enhance our predictive model for treatment responses. Finally, prepare a detailed report summarizing the key immunological characteristics of the tumor, with a focus on the most significant results from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"For my white male patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been conducted, and the tumor mutational burden (TMB) is reported as nan. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been conducted, and the tumor mutational burden (TMB) is reported as nan. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing this evaluation, add the new data to our existing COMPASS dataset to refine our predictive model for treatment responses. Finally, compile a detailed report that summarizes the key immunological characteristics of the tumor, emphasizing the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I have obtained a transcriptomic immune profile from a bladder biopsy, and his tumor mutational burden is 3.0. Based on these parameters, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I have obtained a transcriptomic immune profile from a bladder biopsy, and his tumor mutational burden is 3.0. Based on these parameters, what is the likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS platform to evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells in the tumor microenvironment. Once the analysis is complete, integrate these new data points into our current COMPASS dataset to enhance our predictive model for treatment responses. Lastly, prepare a comprehensive report that outlines the primary immunological features of the tumor, highlighting the most critical findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"For an Asian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to assess the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing the analysis, incorporate the new data into our existing COMPASS dataset to enhance the predictive model for treatment responses. Finally, develop a detailed report summarizing the key immunological features of the tumor, emphasizing the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"I have a white male patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor's immune microenvironment from a bladder biopsy, although the tumor mutation burden (TMB) data is not available. Based on these findings, what is the estimated likelihood that he will have a favorable response to Atezolizumab therapy?","I have a white male patient diagnosed with bladder urothelial carcinoma. We obtained a transcriptomic profile of his tumor's immune microenvironment from a bladder biopsy, although the tumor mutation burden (TMB) data is not available. Based on these findings, what is the estimated likelihood that he will have a favorable response to Atezolizumab therapy? Please utilize the COMPASS platform to analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once the analysis is complete, integrate this new data into our existing COMPASS dataset in order to refine the predictive model for treatment responses. Finally, prepare a comprehensive report detailing the key immunological characteristics of the tumor, with a focus on the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"For my Caucasian female patient with bladder urothelial carcinoma (BLCA), a ureter biopsy provided a transcriptomic profile of the tumor immune microenvironment, and her tumor mutational burden is 12.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma (BLCA), a ureter biopsy provided a transcriptomic profile of the tumor immune microenvironment, and her tumor mutational burden is 12.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to evaluate the gene expression patterns of natural killer cells, exhausted T cells, B cells, and plasma cells in the tumor microenvironment. After completing this analysis, incorporate the new data into our current COMPASS dataset to enhance the treatment response predictive model. Lastly, generate a detailed report that emphasizes the key immunological features of the tumor, highlighting the most important findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy was performed, but the tumor mutational burden is not available. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy was performed, but the tumor mutational burden is not available. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to assess the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you have completed this evaluation, incorporate the new data into our existing COMPASS dataset to refine our treatment response predictive model. Finally, compile a detailed report that outlines the key immunological characteristics of the tumor, emphasizing the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"For my white female patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0 mutations per megabase. Based on these findings, what is the estimated likelihood of her responding positively to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0 mutations per megabase. Based on these findings, what is the estimated likelihood of her responding positively to Atezolizumab therapy? Please use the COMPASS platform to profile the gene expression of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing the analysis, update our current COMPASS dataset with these findings to improve our treatment response predictive model. Finally, prepare a comprehensive report detailing the key immunologic characteristics of the tumor, with particular emphasis on the most significant observations from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"For my white male patient with bladder urothelial carcinoma, a lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden is 4.0. Based on these parameters, what is the estimated likelihood that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden is 4.0. Based on these parameters, what is the estimated likelihood that he will respond favorably to Atezolizumab therapy? Please use the COMPASS platform to profile the gene expression of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you have completed the analysis, update our current COMPASS dataset with these findings to refine our predictive model for treatment response. Finally, compile a detailed report that focuses on the key immunologic characteristics of the tumor, emphasizing the most significant observations from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 8.0 and for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 8.0 and for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells found in the tumor microenvironment. After completing the analysis, update the current COMPASS dataset with these new findings to enhance our predictive model for treatment response. Finally, prepare a detailed report that outlines the key immunologic features of the tumor, emphasizing the most significant observations from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"For a white patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The tumor mutational burden (TMB) is unavailable. Based on these data, how likely is it that the patient will respond favorably to Atezolizumab therapy?","For a white patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The tumor mutational burden (TMB) is unavailable. Based on these data, how likely is it that the patient will respond favorably to Atezolizumab therapy? Please utilize the COMPASS platform to examine the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells present within the tumor microenvironment. Once your analysis is complete, update our current COMPASS dataset with these new data to refine our predictive model for treatment response. Lastly, generate a detailed report summarizing the key immunologic characteristics observed in the tumor, with particular emphasis on the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"For my Black or African American male patient with Bladder Urothelial Carcinoma, whose transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden of 1.0, what is the likelihood of a positive response to Atezolizumab therapy?","For my Black or African American male patient with Bladder Urothelial Carcinoma, whose transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden of 1.0, what is the likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and analyze the gene expression profiles for natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing your evaluation, update the existing COMPASS dataset with the new data to enhance our predictive model for treatment response. Additionally, prepare a detailed report that outlines the key immunologic features identified in the tumor, highlighting the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"For an Asian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 11.0 and whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 11.0 and whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and review the gene expression profiles for natural killer cells, exhausted T cells, B cells, and plasma cells in the tumor microenvironment. Once you have completed your analysis, update the existing COMPASS dataset with your new findings to improve our predictive model for treatment response. Additionally, generate a comprehensive report that details the key immunologic features observed in the tumor, with an emphasis on the most significant results of your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 8.0 and whose tumor immune microenvironment was characterized via transcriptomic profiling from a kidney biopsy, how likely is it that he will respond favorably to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 8.0 and whose tumor immune microenvironment was characterized via transcriptomic profiling from a kidney biopsy, how likely is it that he will respond favorably to Atezolizumab therapy? Please access the COMPASS platform and examine the gene expression profiles for natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing your evaluation, update the COMPASS dataset with your findings to enhance our predictive model for treatment response. Also, compile a detailed report that highlights the key immunologic features observed in the tumor, emphasizing the most noteworthy results of your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"For a white female patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 7.0, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden of 7.0, what is the estimated likelihood of a favorable response to atezolizumab therapy? Access the COMPASS platform and review the gene expression profiles associated with natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you have completed your evaluation, update the COMPASS dataset with your findings to refine our predictive model for treatment response. Additionally, please prepare a comprehensive report detailing the key immunologic features observed, with an emphasis on the most significant findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment was obtained from an additional biopsy, but the Tumor Mutational Burden (TMB) value is not available. Based on these findings, can we estimate the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment was obtained from an additional biopsy, but the Tumor Mutational Burden (TMB) value is not available. Based on these findings, can we estimate the likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and examine the gene expression profiles for natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing your review, update the COMPASS dataset with your findings to help enhance our treatment response predictive model. Additionally, compile a detailed report that highlights the key immunologic features you observed, with particular focus on the most noteworthy results from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment was obtained from a bladder biopsy, and the tumor mutational burden (TMB) is 5.0. Based on these parameters, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment was obtained from a bladder biopsy, and the tumor mutational burden (TMB) is 5.0. Based on these parameters, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and review the gene expression profiles for natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you have completed your analysis, update the COMPASS dataset with your findings to support the enhancement of our treatment response predictive model. Additionally, prepare a comprehensive report that details the key immunologic features observed, emphasizing the most significant results from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"In a white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy and measured a tumor mutation burden of 8.0. Based on these parameters, what is the estimated likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy and measured a tumor mutation burden of 8.0. Based on these parameters, what is the estimated likelihood of a positive response to atezolizumab therapy? As a clinician, please log into the COMPASS platform and examine the gene expression profiles related to natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you complete your analysis, update the COMPASS dataset with your observations to refine our treatment response prediction model. Furthermore, provide a detailed report that highlights the most important immunologic findings from your review.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"In my white female patient with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 14.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In my white female patient with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 14.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS platform and review the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells present in the tumor microenvironment. After completing your analysis, update the COMPASS dataset with your observations to enhance our treatment response prediction model. Additionally, prepare and submit a detailed report summarizing the key immunologic findings identified during your review.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile shows a tumor mutation burden of 13.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile shows a tumor mutation burden of 13.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS platform and examine the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once your analysis is complete, update the COMPASS dataset with your findings to improve our treatment response prediction model. Additionally, compile and submit a detailed report outlining the key immunologic insights from your review.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"For my Asian male patient with bladder urothelial carcinoma (BLCA), whose tumor biopsy analysis indicates a transcriptomic immune microenvironment profile and a TMB of 14.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Asian male patient with bladder urothelial carcinoma (BLCA), whose tumor biopsy analysis indicates a transcriptomic immune microenvironment profile and a TMB of 14.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and analyze the gene expression data for natural killer cells, exhausted T cells, B cells, and plasma cells present in the tumor microenvironment. After completing your review, update the COMPASS dataset with your findings to help refine our treatment response prediction model. Additionally, compile a detailed report summarizing the key immunologic insights from your analysis and submit it as part of your review process.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"For our White male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0, based on transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For our White male patient with bladder urothelial carcinoma and a tumor mutational burden of 7.0, based on transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and examine the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you complete the analysis, update the COMPASS dataset with your findings to enhance our treatment response prediction model. Also, prepare a detailed report summarizing the key immunologic insights from your analysis and submit it as part of your review.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Given a tumor mutation burden of 6.0, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of his tumor immune microenvironment from a bladder biopsy. Given a tumor mutation burden of 6.0, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please access the COMPASS platform and analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing your analysis, update the COMPASS dataset with the new findings to refine our treatment response prediction model. Additionally, prepare a comprehensive report that summarizes the key immunologic insights from your analysis and submit it as part of your review.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"For my Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy. With a tumor mutational burden (TMB) of 6.0, what is the likelihood of a favorable response to Atezolizumab treatment?","For my Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy. With a tumor mutational burden (TMB) of 6.0, what is the likelihood of a favorable response to Atezolizumab treatment? Please log into the COMPASS platform and evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells present in the tumor microenvironment. Once you have completed your analysis, update the COMPASS dataset with the new data to refine our treatment response prediction model. Additionally, prepare and submit a detailed report summarizing the key immunologic insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and transcriptomic profiling data from the tumor immune microenvironment obtained via bladder biopsy, how would you estimate the likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 5.0 and transcriptomic profiling data from the tumor immune microenvironment obtained via bladder biopsy, how would you estimate the likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS platform and analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing your evaluation, update the COMPASS dataset with this new information to enhance our treatment response prediction model. Finally, compile and submit a comprehensive report summarizing the primary immunologic findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"For my Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 49.0, what is the likelihood of a positive response to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutation burden (TMB) of 49.0, what is the likelihood of a positive response to atezolizumab therapy? Access the COMPASS platform to evaluate gene expression levels in natural killer cells, exhausted T cells, B cells, and plasma cells located within the tumor microenvironment. Once your analysis is complete, please update the COMPASS dataset with these findings to refine our treatment response prediction model. Finally, generate a detailed report that summarizes the key immunologic insights from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"For a White male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 12.0. Based on these findings, what is the likelihood of a positive clinical response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden (TMB) of 12.0. Based on these findings, what is the likelihood of a positive clinical response to Atezolizumab therapy? Please log in to the COMPASS platform and assess gene expression levels in natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing your evaluation, update the COMPASS dataset with your findings to improve our treatment response prediction model. Finally, compile a comprehensive report summarizing the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"For my white male patient with bladder urothelial carcinoma, I have obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. The analysis indicates a tumor mutation burden (TMB) value of nan. Based on these parameters, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I have obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. The analysis indicates a tumor mutation burden (TMB) value of nan. Based on these parameters, what is the likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and analyze gene expression levels for natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once your analysis is complete, update the COMPASS dataset to enhance our treatment response prediction model. Finally, prepare a detailed report summarizing the key immunological findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS platform and evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing your analysis, update the COMPASS dataset to refine our treatment response prediction model. Finally, prepare a comprehensive report summarizing the significant immunological findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"For my African American male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 11.0 and transcriptomic profiling data of the tumor immune microenvironment from a kidney biopsy, what is the expected likelihood of a positive response to atezolizumab therapy?","For my African American male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 11.0 and transcriptomic profiling data of the tumor immune microenvironment from a kidney biopsy, what is the expected likelihood of a positive response to atezolizumab therapy? Please log in to the COMPASS platform and analyze the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once the analysis is complete, update the COMPASS dataset accordingly to enhance our treatment response prediction model. Finally, compile a detailed report outlining the key immunological findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Given that the tumor mutational burden (TMB) is reported as ""nan,"" how likely is it that the patient will have a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Given that the tumor mutational burden (TMB) is reported as ""nan,"" how likely is it that the patient will have a positive response to Atezolizumab therapy? Please log in to the COMPASS platform and evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing the analysis, update the COMPASS dataset to improve the treatment response prediction model. Finally, prepare a comprehensive report that summarizes the key immunological findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"For my white male patient with bladder urothelial carcinoma, a ureter biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden data is unavailable. Based on these findings, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a ureter biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden data is unavailable. Based on these findings, what is the estimated likelihood of a positive response to atezolizumab therapy? Please access the COMPASS platform to assess the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells present in the tumor microenvironment. Once your evaluation is complete, incorporate your findings into the current COMPASS dataset to enhance our treatment response prediction model. Finally, generate a detailed report that outlines the key immunological observations derived from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"For a white male patient with bladder urothelial carcinoma who has a TMB of 17.0 and available transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a TMB of 17.0 and available transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment, what is the expected likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and evaluate the gene expression profiles of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once you finish your analysis, incorporate your findings into the current COMPASS dataset to further refine our treatment response prediction model. Finally, compile a detailed report summarizing the key immunological insights from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"For a white male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 22.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the predicted likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 22.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the predicted likelihood of a favorable response to Atezolizumab therapy? Please log in to the COMPASS platform and perform a gene expression analysis focusing on natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing your evaluation, update the existing COMPASS dataset with your results to enhance our treatment response prediction model. Finally, prepare a comprehensive report that outlines the key immunological insights derived from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, with a tumor mutation burden (TMB) reported as ""nan."" Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, with a tumor mutation burden (TMB) reported as ""nan."" Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and conduct a gene expression analysis concentrating on natural killer cells, exhausted T cells, B cells, and plasma cells present within the tumor microenvironment. Once your analysis is complete, update the current COMPASS dataset with your findings to improve our treatment response prediction model. Additionally, compile a detailed report highlighting the principal immunological insights from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"For our patient with bladder urothelial carcinoma, whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment shows a TMB of 18.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For our patient with bladder urothelial carcinoma, whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment shows a TMB of 18.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and perform a gene expression analysis focused on natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing your analysis, update the existing COMPASS dataset with your results to enhance the accuracy of our treatment response prediction model. Additionally, compile a comprehensive report that summarizes the key immunological findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"For a Caucasian patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0, based on transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0, based on transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy? Please access the COMPASS platform and perform a gene expression analysis focusing on natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once completed, update the COMPASS dataset with your findings to enhance the accuracy of our treatment response prediction model. Additionally, prepare a comprehensive report summarizing the key immunological insights from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 4.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 4.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Access the COMPASS platform to conduct a gene expression analysis with an emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing the evaluation, please update the COMPASS dataset with your findings to improve the accuracy of our treatment response prediction model. In addition, compile a detailed report that summarizes the key immunological insights identified through your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"For our white male patient diagnosed with bladder urothelial carcinoma, a kidney biopsy revealed a transcriptomic profile of the tumor immune microenvironment indicating a tumor mutational burden of 5.0. What is the estimated likelihood of a positive response to Atezolizumab therapy based on these parameters?","For our white male patient diagnosed with bladder urothelial carcinoma, a kidney biopsy revealed a transcriptomic profile of the tumor immune microenvironment indicating a tumor mutational burden of 5.0. What is the estimated likelihood of a positive response to Atezolizumab therapy based on these parameters? Please log into the COMPASS platform and perform a gene expression analysis targeting specific immune populations within the tumor microenvironment, including natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, update the COMPASS dataset with your findings to refine our treatment response prediction model. Also, compile a detailed report summarizing the key immunological insights derived from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, whose kidney biopsy and transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden of 12.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, whose kidney biopsy and transcriptomic profiling of the tumor immune microenvironment revealed a tumor mutational burden of 12.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and conduct a gene expression analysis focusing on specific immune cell populations within the tumor microenvironment, namely natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, update the COMPASS dataset with your results to enhance our treatment response prediction model. Additionally, prepare a detailed report outlining the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"For my Caucasian patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment was obtained from a liver biopsy, and the TMB could not be determined. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment was obtained from a liver biopsy, and the TMB could not be determined. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and perform a gene expression analysis targeting immune cell subsets within the tumor microenvironment: natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, update the COMPASS dataset with your findings to refine our treatment response prediction model. Additionally, compile a detailed report summarizing the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"For a white female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, but the tumor mutation burden (TMB) could not be determined (nan). Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, but the tumor mutation burden (TMB) could not be determined (nan). Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and conduct a gene expression analysis focusing on specific immune cell subsets within the tumor microenvironment, namely natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, update the COMPASS dataset with your findings to enhance our treatment response prediction model. Additionally, prepare a detailed report summarizing the key immunological findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma (BLCA), the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy shows a tumor mutational burden of 10.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma (BLCA), the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy shows a tumor mutational burden of 10.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and perform a gene expression analysis targeting specific immune cells within the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, update the COMPASS dataset with your findings to improve our treatment response prediction model. Finally, generate a detailed report outlining the main immunological insights from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"For my Caucasian female patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy and noted a tumor mutational burden of 6.0. Based on these data, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy and noted a tumor mutational burden of 6.0. Based on these data, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS platform and conduct a gene expression analysis concentrating on immune cell subsets within the tumor microenvironment, including natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is completed, update the COMPASS dataset with the new findings to refine our treatment response prediction model. Finally, compile a comprehensive report that details the key immunological insights from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows an indeterminate tumor mutational burden, what is the expected likelihood of a favorable response to atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows an indeterminate tumor mutational burden, what is the expected likelihood of a favorable response to atezolizumab therapy? Please log in to the COMPASS platform and perform a gene expression analysis focused on immune cell subsets within the tumor microenvironment, specifically natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, update the COMPASS dataset with your new findings to enhance our treatment response prediction model. Finally, prepare a detailed report summarizing the key immunological insights from your investigation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"For my white female patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of her tumor’s immune microenvironment from a bladder biopsy, and her tumor mutational burden is 15. Based on these findings, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of her tumor’s immune microenvironment from a bladder biopsy, and her tumor mutational burden is 15. Based on these findings, what is the estimated likelihood of a favorable response to atezolizumab therapy? Please log in to the COMPASS platform and conduct a gene expression analysis with a focus on immune cell subsets in the tumor microenvironment. Specifically, analyze natural killer cells, exhausted T cells, B cells, and plasma cells. After your analysis, update the COMPASS dataset with your findings to refine our treatment response prediction model. Finally, compile a detailed report summarizing the key immunological insights from your investigation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose lymph node biopsy of the tumor's immune microenvironment reveals a tumor mutation burden (TMB) of 8.0 mutations/Mb, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose lymph node biopsy of the tumor's immune microenvironment reveals a tumor mutation burden (TMB) of 8.0 mutations/Mb, what is the expected likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform to perform a gene expression analysis targeting specific immune cell subsets within the tumor microenvironment. In your analysis, emphasize the assessment of natural killer cells, exhausted T cells, B cells, and plasma cells. Once completed, update the COMPASS dataset with your results to enhance our treatment response prediction model. Finally, prepare a comprehensive report that details the key immunological insights observed during your investigation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"For our white patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 6.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For our white patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 6.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and perform a gene expression analysis focusing on immune cell subsets within the tumor microenvironment. Specifically, evaluate natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, update the COMPASS dataset with your findings to improve our treatment response prediction model. Finally, develop a detailed report that summarizes the key immunological insights from your investigation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"For my Caucasian male patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy revealed a tumor mutational burden of 19.0. Based on these findings, what is the likely response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy revealed a tumor mutational burden of 19.0. Based on these findings, what is the likely response to Atezolizumab therapy? Please log into the COMPASS platform and conduct a gene expression analysis targeting immune cell subsets within the tumor microenvironment, specifically focusing on natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, update the COMPASS dataset with your results to enhance our treatment response prediction model. Finally, compile a detailed report summarizing the key immunological findings from your investigation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"For my White patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a recent biopsy, which showed a tumor mutational burden of 12.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","For my White patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a recent biopsy, which showed a tumor mutational burden of 12.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please access the COMPASS platform and perform a gene expression analysis targeting immune cell subsets within the tumor microenvironment, with particular emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, update the COMPASS dataset with your findings to refine our treatment response prediction model. Finally, prepare a comprehensive report that details the key immunological insights derived from your investigation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"For my White male patient with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, though the tumor mutation burden data is unavailable. Based on these findings, what is the likelihood of a positive response to Atezolizumab?","For my White male patient with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, though the tumor mutation burden data is unavailable. Based on these findings, what is the likelihood of a positive response to Atezolizumab? Please log into the COMPASS platform and conduct a gene expression analysis focused on immune cell subsets within the tumor microenvironment, specifically natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, update the COMPASS dataset with your results to improve our treatment response prediction model. Finally, compile a detailed report outlining the main immunological findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and a transcriptomic profile of his tumor immune microenvironment obtained via bladder biopsy, what is the likelihood that he will respond favorably to atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 3.0 and a transcriptomic profile of his tumor immune microenvironment obtained via bladder biopsy, what is the likelihood that he will respond favorably to atezolizumab therapy? Please access the COMPASS platform and perform a gene expression analysis that centers on immune cell subsets—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—in the tumor microenvironment. Once you have completed your analysis, update the COMPASS dataset with your findings to help refine our treatment response prediction model. Additionally, compile a detailed report summarizing the key immunological insights from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"For a white male patient with bladder urothelial carcinoma, based on a lymph node biopsy–derived transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 18.0, how likely is a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, based on a lymph node biopsy–derived transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 18.0, how likely is a positive response to Atezolizumab therapy? Please log in to the COMPASS platform and conduct a gene expression analysis focused on immune cell subsets within the tumor microenvironment, specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After obtaining the results, update the COMPASS dataset accordingly to refine our treatment response prediction model, and prepare a detailed report outlining the key immunological discoveries from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"For my white male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. With a tumor mutational burden of 15, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. With a tumor mutational burden of 15, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and perform a gene expression analysis on immune cell subsets in the tumor microenvironment, specifically targeting natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have the results, update the COMPASS dataset to enhance our treatment response prediction model and prepare a detailed report summarizing the key immunological findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, although the tumor mutational burden (TMB) was not assessable. Based on these findings, what is the likelihood of a positive response to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, although the tumor mutational burden (TMB) was not assessable. Based on these findings, what is the likelihood of a positive response to atezolizumab therapy? Please log into the COMPASS platform and conduct a gene expression analysis focusing on immune cell subsets in the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, update the COMPASS dataset with your findings to improve our treatment response prediction model. Also, prepare a comprehensive report detailing the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"For a white female patient with bladder urothelial carcinoma, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and an unspecified tumor mutational burden, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and an unspecified tumor mutational burden, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please sign into the COMPASS platform and perform a gene expression analysis focusing on immune cell populations within the tumor microenvironment, particularly natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, update the COMPASS dataset with your results to refine our treatment response prediction model. Additionally, prepare a detailed report summarizing the key immunological findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized via a kidney biopsy and has a tumor mutational burden of 6.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized via a kidney biopsy and has a tumor mutational burden of 6.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS platform and conduct a gene expression analysis focusing on immune cells within the tumor microenvironment, with special attention to natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, update the COMPASS dataset with your findings to improve our treatment response prediction model. Additionally, compile a detailed report outlining the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"For my white female patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and her TMB value is reported as nan. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and her TMB value is reported as nan. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS platform and perform a gene expression analysis of immune cells present in the tumor microenvironment. Your analysis should specifically target natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, update the COMPASS dataset with your results to help refine our treatment response prediction model. Additionally, prepare a comprehensive report that summarizes the key immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"In a Black/African American patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment was obtained from a ureter biopsy, and the tumor mutational burden is reported as ""nan."" Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy?","In a Black/African American patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment was obtained from a ureter biopsy, and the tumor mutational burden is reported as ""nan."" Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy? Please access the COMPASS platform and conduct a gene expression analysis focusing on immune cells within the tumor microenvironment. Specifically, analyze natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, update the COMPASS dataset with your findings to improve our treatment response prediction model. Finally, compile a detailed report summarizing the key immunological insights derived from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"In a white female patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy was performed, and the tumor mutational burden (TMB) was reported as ""nan."" Based on this data, what is the estimated likelihood of a favorable response to atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy was performed, and the tumor mutational burden (TMB) was reported as ""nan."" Based on this data, what is the estimated likelihood of a favorable response to atezolizumab therapy? Please log into the COMPASS platform and perform a gene expression analysis focusing on immune cell populations within the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, update the COMPASS dataset with your findings to enhance our current treatment response prediction model. Finally, prepare a detailed report summarizing the primary immunological insights gained from the study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"For a white male patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic analysis of the tumor immune microenvironment shows a TMB of 4.0, what are the prospects of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic analysis of the tumor immune microenvironment shows a TMB of 4.0, what are the prospects of a positive response to Atezolizumab therapy? Please access the COMPASS platform and carry out a gene expression analysis specifically targeting immune cell subsets—namely natural killer cells, exhausted T cells, B cells, and plasma cells—in the tumor microenvironment. After completing your analysis, update the COMPASS dataset with your findings to refine our treatment response prediction model. Finally, compile a comprehensive report that summarizes the key immunological insights derived from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Given his tumor mutation burden of 14.0, what is the probability of a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Given his tumor mutation burden of 14.0, what is the probability of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and conduct a gene expression analysis focusing on key immune cell subsets in the tumor microenvironment, specifically natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have completed the analysis, update the COMPASS dataset with your results to improve our treatment response prediction model. Finally, prepare a detailed report summarizing the main immunological insights uncovered in your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"For my Caucasian male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy, and his tumor mutational burden is 7.0. How likely is he to benefit from atezolizumab therapy based on these findings?","For my Caucasian male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy, and his tumor mutational burden is 7.0. How likely is he to benefit from atezolizumab therapy based on these findings? Please access the COMPASS platform and perform a gene expression analysis targeting key immune cell populations in the tumor microenvironment, specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, update the COMPASS dataset with your findings to refine our treatment response prediction model. Finally, prepare a comprehensive report detailing the primary immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"In a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 3.0 and whose tumor immune microenvironment transcriptomic profile was obtained via a lung biopsy, what is the expected likelihood of a positive response to atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 3.0 and whose tumor immune microenvironment transcriptomic profile was obtained via a lung biopsy, what is the expected likelihood of a positive response to atezolizumab therapy? Please log in to the COMPASS platform and conduct a gene expression analysis focused on key immune cell populations within the tumor microenvironment—namely, natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, update the COMPASS dataset with your results to enhance our treatment response prediction model. Finally, compile a detailed report that outlines the primary immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"For a white male patient with bladder urothelial carcinoma, a bladder biopsy has provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden is 11.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, a bladder biopsy has provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden is 11.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and perform a gene expression analysis targeting key immune cell types within the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, update the COMPASS dataset with your findings to improve our treatment response prediction model. Finally, prepare a detailed report summarizing the primary immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"For a white female patient with bladder urothelial carcinoma, whose transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 4.0, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden (TMB) of 4.0, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and conduct a gene expression analysis focusing on critical immune cell populations within the tumor microenvironment—specifically, natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have completed the analysis, update the COMPASS dataset with your findings to refine our treatment response prediction model. Finally, prepare a comprehensive report outlining the key immunological insights derived from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"For a white female patient with bladder urothelial carcinoma, we obtained transcriptomic profiling of the tumor immune microenvironment from her bladder biopsy, and her tumor mutational burden is reported as ""nan."" Based on these findings, how likely is she to achieve a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, we obtained transcriptomic profiling of the tumor immune microenvironment from her bladder biopsy, and her tumor mutational burden is reported as ""nan."" Based on these findings, how likely is she to achieve a positive response to Atezolizumab therapy? Log into the COMPASS platform and perform a gene expression analysis targeting key immune cell types in the tumor microenvironment—namely, natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, update the COMPASS dataset with your findings to enhance our treatment response prediction model. Finally, prepare a detailed report summarizing the primary immunological insights from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"For my white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, and the tumor mutation burden is reported as ""nan."" Given these findings, how might we assess his likelihood of responding favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, and the tumor mutation burden is reported as ""nan."" Given these findings, how might we assess his likelihood of responding favorably to Atezolizumab therapy? Please log into the COMPASS platform and conduct a gene expression analysis focusing on key immune cell types—specifically, natural killer cells, exhausted T cells, B cells, and plasma cells—within the tumor microenvironment. Once the analysis is complete, update the COMPASS dataset with your findings to help improve our treatment response prediction model. Finally, prepare a detailed report that summarizes the main immunological insights from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"For a white male patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a separate biopsy and a TMB of 18.0, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a separate biopsy and a TMB of 18.0, what is the likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and perform a gene expression analysis concentrating on specific immune cell populations—namely, natural killer cells, exhausted T cells, B cells, and plasma cells—in the tumor microenvironment. After completing your analysis, update the COMPASS dataset with the new data to enhance our treatment response prediction model. Additionally, compile a comprehensive report detailing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"For our White male patient with bladder urothelial carcinoma (BLCA), whose transcriptomic profile of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 19.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For our White male patient with bladder urothelial carcinoma (BLCA), whose transcriptomic profile of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 19.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and perform a gene expression analysis focusing on key immune cell populations in the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. Once you've completed the analysis, update the COMPASS dataset with the new data to refine our treatment response prediction model. Finally, prepare and submit a detailed report summarizing the main immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"For our white male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, revealing a tumor mutation burden of 35.0. What is the estimated likelihood of a positive response to Atezolizumab therapy based on these findings?","For our white male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, revealing a tumor mutation burden of 35.0. What is the estimated likelihood of a positive response to Atezolizumab therapy based on these findings? Please access the COMPASS platform and conduct a gene expression analysis examining key immune cell populations within the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, update the COMPASS dataset with the new information to enhance our treatment response prediction model. Finally, prepare and submit a detailed report summarizing the main immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"For my white male patient with bladder urothelial carcinoma, whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and shows a TMB of 5.0, how likely is a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and shows a TMB of 5.0, how likely is a positive response to atezolizumab therapy? Please log into the COMPASS platform and perform a gene expression analysis focusing on key immune cell populations—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—within the tumor microenvironment. Once your analysis is complete, update the COMPASS dataset with the new findings to improve our treatment response prediction model. Finally, compile a comprehensive report that clearly summarizes your main immunological findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"For my white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 5.0 mutations per megabase. Based on these parameters, what is the estimated likelihood that the patient will respond positively to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 5.0 mutations per megabase. Based on these parameters, what is the estimated likelihood that the patient will respond positively to atezolizumab therapy? Please access the COMPASS system and conduct a gene expression analysis targeting key immune cell subsets—namely natural killer cells, exhausted T cells, B cells, and plasma cells—within the tumor microenvironment. After completing your analysis, update the COMPASS dataset with the new data to refine our treatment response prediction model. Finally, prepare a detailed report summarizing your primary immunological findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"In our white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment was performed on a bladder biopsy. Given a tumor mutational burden of 16.0, what is the likelihood that this patient will respond positively to atezolizumab therapy?","In our white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment was performed on a bladder biopsy. Given a tumor mutational burden of 16.0, what is the likelihood that this patient will respond positively to atezolizumab therapy? Please log in to the COMPASS system and perform a gene expression analysis focusing on the following immune cell populations in the tumor microenvironment: natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, update the COMPASS dataset with the new findings to enhance our treatment response prediction model. Additionally, compile a detailed report that summarizes the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"For my patient with bladder urothelial carcinoma who exhibits a tumor mutational burden of 8.0 and has undergone transcriptomic profiling of the tumor immune microenvironment via bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For my patient with bladder urothelial carcinoma who exhibits a tumor mutational burden of 8.0 and has undergone transcriptomic profiling of the tumor immune microenvironment via bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS system and conduct a gene expression analysis targeting natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing the analysis, update the COMPASS dataset with the new data to refine our treatment response prediction model. Also, please prepare a comprehensive report that outlines the critical immunological insights from your findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"For my Caucasian patient with bladder urothelial carcinoma, what is the likelihood of a positive response to atezolizumab therapy given a tumor mutation burden of 5.0 and the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy?","For my Caucasian patient with bladder urothelial carcinoma, what is the likelihood of a positive response to atezolizumab therapy given a tumor mutation burden of 5.0 and the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy? Please log into the COMPASS system and perform a gene expression analysis focusing on natural killer cells, exhausted T cells, B cells, and plasma cells present in the tumor microenvironment. Once you have completed the analysis, kindly update the COMPASS dataset with the new findings to enhance our treatment response prediction model. Additionally, prepare a detailed report summarizing the key immunological insights uncovered during your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"In a white patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and a tumor mutational burden of 5.0. Based on these parameters, what is the predicted likelihood of a favorable response to Atezolizumab therapy?","In a white patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy and a tumor mutational burden of 5.0. Based on these parameters, what is the predicted likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS system and perform a comprehensive gene expression analysis with a specific focus on natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing your analysis, update the COMPASS dataset with these new findings to refine our treatment response prediction model. Additionally, prepare a detailed report that summarizes the key immunological insights obtained from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 7.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 7.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS system and conduct a detailed gene expression analysis concentrating on natural killer cells, exhausted T cells, B cells, and plasma cells present in the tumor microenvironment. Once your analysis is complete, update the COMPASS dataset with your findings to improve our treatment response prediction model. Additionally, compile a comprehensive report outlining the principal immunological insights your analysis has uncovered.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden data is unavailable. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden data is unavailable. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS system and perform an in-depth gene expression analysis focused on natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Following your analysis, update the COMPASS dataset with the new findings to enhance our treatment response prediction model. Additionally, prepare a detailed report summarizing the key immunological insights derived from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"For my white male patient with bladder urothelial carcinoma, we recently obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 9.0. Based on these findings, what is the likelihood that he will respond positively to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, we recently obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 9.0. Based on these findings, what is the likelihood that he will respond positively to Atezolizumab therapy? Please access the COMPASS system and conduct a comprehensive gene expression analysis targeting natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once your analysis is complete, update the COMPASS dataset with these new findings to refine our treatment response prediction model. Additionally, generate a detailed report that summarizes the key immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"For my white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profiling of the tumor immune microenvironment reveals a tumor mutation burden (TMB) of 20 mutations per megabase, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profiling of the tumor immune microenvironment reveals a tumor mutation burden (TMB) of 20 mutations per megabase, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS system and perform an in-depth gene expression analysis focusing on natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing the analysis, update the COMPASS dataset with your new findings to improve our treatment response prediction model. Finally, prepare a detailed report that outlines the key immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"In a white female patient with bladder urothelial carcinoma who has a tumor mutational burden of 10.0 and given the transcriptomic profile obtained from a lymph node biopsy of the tumor immune microenvironment, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma who has a tumor mutational burden of 10.0 and given the transcriptomic profile obtained from a lymph node biopsy of the tumor immune microenvironment, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS system and perform a comprehensive gene expression analysis targeting natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once the analysis is complete, incorporate your new data into the COMPASS dataset to enhance our treatment response prediction model. Finally, compile a detailed report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"For a white male patient with bladder urothelial carcinoma presenting a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 35.0, what is the likelihood of a positive therapeutic response to Atezolizumab?","For a white male patient with bladder urothelial carcinoma presenting a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 35.0, what is the likelihood of a positive therapeutic response to Atezolizumab? Access the COMPASS system and perform a comprehensive gene expression analysis focusing on natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. Once completed, integrate your findings into the COMPASS dataset to refine our treatment response prediction model. Finally, prepare a detailed report outlining the key immunological observations from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"For a Caucasian female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 6.0 mutations per Mb. Based on these molecular characteristics, how likely is the patient to exhibit a favorable response to Atezolizumab therapy?","For a Caucasian female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 6.0 mutations per Mb. Based on these molecular characteristics, how likely is the patient to exhibit a favorable response to Atezolizumab therapy? Please log into the COMPASS system and conduct a thorough gene expression analysis of natural killer cells, exhausted T cells, B cells, and plasma cells within the tumor microenvironment. After completing the analysis, add your results to the COMPASS dataset to improve our treatment response prediction model. Finally, compile a detailed report that outlines the key immunological findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"For my white female patient with bladder urothelial carcinoma, who has a tumor mutation burden of 3.0 and available transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment, how likely is she to have a positive response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, who has a tumor mutation burden of 3.0 and available transcriptomic data from a bladder biopsy detailing the tumor immune microenvironment, how likely is she to have a positive response to Atezolizumab therapy? Please access the COMPASS system and perform a detailed gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells derived from the tumor microenvironment. Once completed, incorporate your findings into the COMPASS dataset to help optimize our treatment response prediction model. Finally, produce a comprehensive report that clearly outlines the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and available transcriptomic data of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and available transcriptomic data of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS system and conduct a thorough gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells isolated from the tumor microenvironment. Once the analysis is complete, update the COMPASS dataset with your findings to refine our treatment response prediction model. Finally, prepare a detailed report that summarizes the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"In a Caucasian patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment via nanobiopsy revealed a tumor mutation burden of 5.0. Based on these results, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a Caucasian patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment via nanobiopsy revealed a tumor mutation burden of 5.0. Based on these results, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS system and perform a comprehensive gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells isolated from the tumor microenvironment. After completing your analysis, update the COMPASS dataset with the new data to enhance our treatment response prediction model. Additionally, compile a detailed report summarizing the key immunological findings from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"For my white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a TMB of 5.0. Based on these findings, how likely is he to respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a TMB of 5.0. Based on these findings, how likely is he to respond favorably to Atezolizumab therapy? Please log into the COMPASS system and conduct a detailed gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells collected from the tumor microenvironment. Once you have completed this analysis, update the COMPASS dataset with your findings to improve our treatment response prediction model. Additionally, prepare a comprehensive report summarizing the key immunological insights from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor transcriptomic profile obtained from a kidney biopsy reveals a tumor mutational burden (TMB) of 5.0, what is the estimated likelihood of a positive response to Atezolizumab treatment?","For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor transcriptomic profile obtained from a kidney biopsy reveals a tumor mutational burden (TMB) of 5.0, what is the estimated likelihood of a positive response to Atezolizumab treatment? Please access the COMPASS system and perform a detailed gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells obtained from the tumor microenvironment. Upon completion of your analysis, be sure to update the COMPASS dataset with your findings to refine our treatment response prediction model. Additionally, compile a comprehensive report that summarizes the key immunological insights derived from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy was performed, but the tumor mutation burden (TMB) could not be determined. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy was performed, but the tumor mutation burden (TMB) could not be determined. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please log into the COMPASS system and conduct a detailed gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells isolated from the tumor microenvironment. Once your analysis is complete, update the COMPASS dataset with your findings to enhance our treatment response prediction model. Additionally, prepare a comprehensive report outlining the key immunological insights from your work.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"In a patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 3.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 3.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS system and perform an in-depth gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells isolated from the tumor microenvironment. Once completed, update the COMPASS dataset with your findings to refine our treatment response prediction model. Additionally, prepare a detailed report summarizing the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"For a white male patient with bladder urothelial carcinoma, whose ureter biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a TMB of 10.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose ureter biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a TMB of 10.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS system and conduct a comprehensive gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells isolated from the tumor microenvironment. After completing the analysis, update the COMPASS dataset with your results so that we can further refine our treatment response prediction model. Additionally, please prepare a detailed report summarizing the key immunological findings from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"For my white male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profile of the tumor immune microenvironment and a TMB of 3.0 have been obtained, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profile of the tumor immune microenvironment and a TMB of 3.0 have been obtained, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS system and perform a detailed gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells isolated from the tumor microenvironment. Once you have completed the analysis, update the COMPASS dataset with your findings to help us refine the treatment response prediction model. In addition, provide a comprehensive report summarizing the key immunological insights derived from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"For a White male patient with bladder urothelial carcinoma (BLCA) exhibiting a tumor mutation burden (TMB) of 3.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma (BLCA) exhibiting a tumor mutation burden (TMB) of 3.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please log in to the COMPASS system and conduct an in-depth gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells isolated from the tumor microenvironment. After completing your analysis, update the COMPASS dataset with the new findings to enhance our treatment response prediction model. Additionally, prepare a detailed report that summarizes the key immunological insights derived from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"For my Black or African American female patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was profiled from a lung biopsy and has a TMB of 11.0, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For my Black or African American female patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was profiled from a lung biopsy and has a TMB of 11.0, what is the expected likelihood of a favorable response to Atezolizumab therapy? Access the COMPASS system and perform a comprehensive gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells isolated from the tumor microenvironment. Once your analysis is complete, update the COMPASS dataset with the new findings to refine our treatment response prediction model. Finally, compile a detailed report that outlines the key immunological insights from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"For a white patient with bladder urothelial carcinoma, after obtaining a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy and noting a tumor mutation burden (TMB) value reported as 'nan', what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a white patient with bladder urothelial carcinoma, after obtaining a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy and noting a tumor mutation burden (TMB) value reported as 'nan', what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please log in to the COMPASS system and conduct a detailed gene expression study on natural killer cells, exhausted T cells, B cells, and plasma cells isolated from the tumor microenvironment. After completing your analysis, update the COMPASS dataset with these findings to improve our treatment response prediction model. Finally, prepare a comprehensive report summarizing the primary immunological insights derived from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA), whose liver biopsy provided a transcriptomic profile of the tumor immune microenvironment and a reported tumor mutational burden (TMB) of nan, what is the likelihood that he will respond positively to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), whose liver biopsy provided a transcriptomic profile of the tumor immune microenvironment and a reported tumor mutational burden (TMB) of nan, what is the likelihood that he will respond positively to Atezolizumab therapy? Please access the COMPASS system using your login credentials. Once logged in, carry out a comprehensive gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells that have been isolated from the tumor microenvironment. After completing your analysis, update the COMPASS dataset with your findings to refine our treatment response prediction model. Finally, prepare a detailed report that summarizes the primary immunological insights derived from your evaluation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"For my white female patient with bladder urothelial carcinoma, whose ureter biopsy-based transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 26.0, what is the likelihood of her responding positively to atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, whose ureter biopsy-based transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 26.0, what is the likelihood of her responding positively to atezolizumab therapy? Please log into the COMPASS system using your credentials. Once you have access, conduct a detailed gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells isolated from the tumor microenvironment. After completing the analysis, update the COMPASS dataset with your results to enhance our treatment response prediction model. Finally, compile a comprehensive report summarizing the key immunological findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is 14.0. Based on these findings, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is 14.0. Based on these findings, what is the estimated likelihood of a positive response to atezolizumab therapy? Please log into the COMPASS system using your username and password. Once you have access, perform a comprehensive gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells that have been isolated from the tumor microenvironment. After completing your analysis, update the COMPASS dataset with your results to refine our treatment response prediction model. Finally, prepare a detailed report that summarizes the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"For a Caucasian male with bladder urothelial carcinoma, who underwent a lung biopsy for transcriptomic profiling of the tumor immune microenvironment and has an indeterminate tumor mutation burden, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male with bladder urothelial carcinoma, who underwent a lung biopsy for transcriptomic profiling of the tumor immune microenvironment and has an indeterminate tumor mutation burden, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS system using your username and password. Once logged in, conduct a thorough gene expression analysis on natural killer cells, exhausted T cells, B cells, and plasma cells that have been isolated from the tumor microenvironment. After completing your analysis, update the COMPASS dataset with your results to improve our treatment response prediction model. Finally, compile a detailed report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"In my Caucasian female patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden (TMB) of 4.0. Given these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In my Caucasian female patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden (TMB) of 4.0. Given these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS system using your username and password. Once you are logged in, perform a comprehensive gene expression analysis on the isolated immune cell populations—natural killer cells, exhausted T cells, B cells, and plasma cells—from the tumor microenvironment. After completing the analysis, update the COMPASS dataset with your results to refine our treatment response prediction model. Finally, prepare a detailed report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis shows a TMB of 3.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic analysis shows a TMB of 3.0, what is the estimated likelihood of a positive response to atezolizumab therapy? Please access the COMPASS system using your username and password. Once logged in, conduct a comprehensive gene expression analysis on the isolated immune cell populations—natural killer cells, exhausted T cells, B cells, and plasma cells—from the tumor microenvironment. After you have completed the analysis, update the COMPASS dataset with your findings to improve our treatment response prediction model. Finally, compile a detailed report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"In a Caucasian male patient with confirmed bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 22. Based on these findings, what is the probability of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with confirmed bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 22. Based on these findings, what is the probability of a favorable response to Atezolizumab therapy? Please log in to the COMPASS system using your assigned username and password. Once logged in, perform a comprehensive gene expression analysis on the isolated immune cell populations—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—extracted from the tumor microenvironment. After completing the analysis, update the COMPASS dataset with your findings to refine our treatment response prediction model. Finally, prepare a detailed report outlining the key immunological observations from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"For my white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, noting that the tumor mutation burden is not available. Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, noting that the tumor mutation burden is not available. Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS system using your assigned username and password. Once logged in, conduct a detailed gene expression analysis on the immune cell populations—specifically natural killer cells, exhausted T cells, B cells, and plasma cells—isolated from the tumor microenvironment. After finalizing the analysis, update the COMPASS dataset with your results to enhance our treatment response prediction model. Finally, prepare a comprehensive report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"In a white female patient with bladder urothelial carcinoma (BLCA) who has a TMB of 3.0 and available transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma (BLCA) who has a TMB of 3.0 and available transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS system using your assigned username and password. Once logged in, perform a comprehensive gene expression analysis on immune cell populations isolated from the tumor microenvironment, focusing on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, update the COMPASS dataset with your findings to improve our treatment response prediction model. Finally, prepare a detailed report summarizing the key immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"For my Caucasian male patient with bladder urothelial carcinoma, whose kidney biopsy revealed a transcriptomic profile of the tumor immune microenvironment and an elevated tumor mutational burden of 62.0, how likely is he to respond favorably to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, whose kidney biopsy revealed a transcriptomic profile of the tumor immune microenvironment and an elevated tumor mutational burden of 62.0, how likely is he to respond favorably to atezolizumab therapy? Please sign into the COMPASS system using your designated username and password. After logging in, conduct a thorough gene expression analysis on immune cells extracted from the tumor microenvironment, with an emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, update the COMPASS dataset with your findings to enhance our treatment response prediction model. Finally, prepare a comprehensive report that details the key immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"For my other male patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a separate biopsy, and his TMB is 14.0. Based on these findings, how likely is he to have a favorable response to Atezolizumab therapy?","For my other male patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a separate biopsy, and his TMB is 14.0. Based on these findings, how likely is he to have a favorable response to Atezolizumab therapy? Please log in to the COMPASS system using your assigned username and password. After accessing the system, perform a detailed gene expression analysis on immune cells derived from the tumor microenvironment, with a specific focus on natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have completed your analysis, update the COMPASS dataset with your results to improve our treatment response prediction model. Finally, prepare a comprehensive report summarizing the key immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, with a lymph node biopsy–derived transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 7.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, with a lymph node biopsy–derived transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 7.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS system using your assigned login credentials. Once logged in, conduct a thorough gene expression analysis on immune cells isolated from the tumor microenvironment, focusing on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, update the COMPASS dataset with your findings to enhance our treatment response prediction model. Finally, compile a detailed report summarizing the key immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"In a patient with bladder urothelial carcinoma who has a tumor mutation burden of 15.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma who has a tumor mutation burden of 15.0 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS system using your assigned credentials. Once logged in, perform a comprehensive gene expression analysis on immune cells isolated from the tumor microenvironment, specifically examining natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, enter your findings into the COMPASS dataset to help refine our treatment response prediction model. Finally, prepare a detailed report that summarizes the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"For our white male patient with bladder urothelial carcinoma (BLCA), the transcriptomic analysis from a kidney biopsy of the tumor immune microenvironment shows a tumor mutational burden of 5.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For our white male patient with bladder urothelial carcinoma (BLCA), the transcriptomic analysis from a kidney biopsy of the tumor immune microenvironment shows a tumor mutational burden of 5.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS system using your assigned credentials. Once you have access, conduct a detailed gene expression analysis on immune cells isolated from the tumor microenvironment, with a particular focus on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, record your findings in the COMPASS dataset to support the refinement of our treatment response prediction model. Finally, compile a comprehensive report that summarizes the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, although the tumor mutational burden data are not available. How might these findings inform the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, although the tumor mutational burden data are not available. How might these findings inform the likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS system using your designated login details. Once logged in, carry out a thorough gene expression analysis on immune cells extracted from the tumor microenvironment, paying special attention to natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, document your findings within the COMPASS dataset to aid in improving our treatment response prediction model. Finally, prepare a detailed report that outlines the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"For our white female patient with bladder urothelial carcinoma, whose ureter biopsy provided a transcriptomic profile of the tumor immune microenvironment and who has a tumor mutational burden reported as ""nan,"" what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For our white female patient with bladder urothelial carcinoma, whose ureter biopsy provided a transcriptomic profile of the tumor immune microenvironment and who has a tumor mutational burden reported as ""nan,"" what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS system using your assigned credentials. Once logged in, perform a detailed gene expression analysis on immune cells taken from the tumor microenvironment. Focus in particular on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, record your findings in the COMPASS dataset to inform improvements to our treatment response prediction model. Finally, compile a comprehensive report summarizing the key immunological insights from your investigation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"In a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 24.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 24.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS system using your assigned credentials. After logging in, perform a detailed gene expression analysis on immune cells extracted from the tumor microenvironment, with special focus on natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, input your findings into the COMPASS dataset to help refine our treatment response prediction model. Finally, prepare a comprehensive report that summarizes the key immunological insights from your investigation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"For a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, though the tumor mutational burden is not available. Based on these findings, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, though the tumor mutational burden is not available. Based on these findings, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS system using your assigned credentials. After logging in, conduct a comprehensive gene expression analysis on immune cells from the tumor microenvironment, focusing primarily on natural killer cells, exhausted T cells, B cells, and plasma cells. Once completed, enter your findings into the COMPASS dataset to enhance our treatment response prediction model. Finally, prepare a detailed report summarizing the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"For my Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, and his tumor mutational burden is 8.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, and his tumor mutational burden is 8.0. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Please sign in to the COMPASS system using your designated credentials. Once logged in, perform a detailed gene expression profiling on immune cells within the tumor microenvironment, with an emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, record your results in the COMPASS dataset to support enhancements in our treatment response prediction model. Lastly, compile a comprehensive report that outlines the primary immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma with a tumor mutational burden of 4.0 and a transcriptomic analysis of the tumor immune microenvironment obtained from a kidney biopsy, what is the predicted likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma with a tumor mutational burden of 4.0 and a transcriptomic analysis of the tumor immune microenvironment obtained from a kidney biopsy, what is the predicted likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS system using your assigned credentials. After accessing your account, conduct a comprehensive gene expression analysis of immune cells within the tumor microenvironment—specifically focusing on natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, enter your results into the COMPASS dataset to aid in refining our treatment response prediction model. Finally, prepare a detailed report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS system using your personal credentials. Once logged in, perform an in-depth gene expression analysis on immune cells within the tumor microenvironment, with a particular focus on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, input your findings into the COMPASS dataset to help enhance our treatment response prediction model. Finally, prepare a detailed report highlighting the key immunological observations from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0, how likely is a positive response to Atezolizumab therapy based on the transcriptomic profile of the tumor immune microenvironment obtained from his bladder biopsy?","For a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 5.0, how likely is a positive response to Atezolizumab therapy based on the transcriptomic profile of the tumor immune microenvironment obtained from his bladder biopsy? Please log into the COMPASS system using your personal credentials. Once you are logged in, conduct a thorough gene expression analysis of immune cells in the tumor microenvironment, with particular emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, enter your results into the COMPASS dataset to help refine our treatment response prediction model. Lastly, compile a detailed report that outlines the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 10.0 mutations per megabase. Based on these findings, what is the likelihood that the patient will have a positive response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 10.0 mutations per megabase. Based on these findings, what is the likelihood that the patient will have a positive response to Atezolizumab therapy? Please access the COMPASS system using your individual username and password. Once you are logged in, perform a comprehensive gene expression analysis of immune cells within the tumor microenvironment—specifically focusing on natural killer cells, exhausted T cells, B cells, and plasma cells. After you have completed your analysis, enter the findings into the COMPASS dataset to improve our treatment response prediction model. Finally, prepare a detailed report that summarizes the key immunological insights from your investigation.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. The tumor mutational burden is reported as nan. Based on these findings, what is the predicted likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. The tumor mutational burden is reported as nan. Based on these findings, what is the predicted likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS system using your unique username and password. Once logged in, conduct a detailed gene expression analysis of immune cells in the tumor microenvironment, with particular emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, record your findings in the COMPASS dataset to refine our treatment response prediction model. Lastly, compile a comprehensive report that outlines the key immunological observations from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy. However, the tumor mutational burden is not available. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy. However, the tumor mutational burden is not available. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS system using your unique username and password. After logging in, perform a comprehensive gene expression analysis targeting the immune cells within the tumor microenvironment, with a focus on natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, enter your results into the COMPASS dataset to improve our treatment response prediction model. Finally, prepare a detailed report summarizing the main immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, with transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 19.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, with transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 19.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS system using your individual username and password. Once authenticated, conduct a detailed gene expression analysis focusing on the immune cells present in the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload your results to the COMPASS dataset to help enhance our treatment response prediction model. Finally, compile a comprehensive report outlining the key immunological findings from your research.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"In a patient with bladder urothelial carcinoma who underwent a ureter biopsy for transcriptomic profiling of the tumor immune microenvironment and has a TMB of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma who underwent a ureter biopsy for transcriptomic profiling of the tumor immune microenvironment and has a TMB of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please sign into the COMPASS system with your individual username and password. Once logged in, perform a comprehensive gene expression analysis of the immune cells in the tumor microenvironment, with a focus on natural killer cells, exhausted T cells, B cells, and plasma cells. Upon completing the analysis, upload your results to the COMPASS dataset to refine our treatment response prediction model. Finally, prepare a detailed report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"For a white female patient with bladder urothelial carcinoma who has a tumor mutation burden of 2.0 based on transcriptomic analysis of the tumor immune microenvironment, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma who has a tumor mutation burden of 2.0 based on transcriptomic analysis of the tumor immune microenvironment, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS system using your individual username and password. Once logged in, conduct a thorough gene expression analysis on the immune cell populations within the tumor microenvironment, with a specific focus on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload the results to the COMPASS dataset to help refine our treatment response prediction model. Finally, compile a detailed report that summarizes the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"For my white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profiling of the tumor immune microenvironment shows a tumor mutational burden of 14.0, what is the likelihood of a favorable response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profiling of the tumor immune microenvironment shows a tumor mutational burden of 14.0, what is the likelihood of a favorable response to atezolizumab therapy? Please log into the COMPASS system using your individual username and password. Once inside, perform a comprehensive gene expression analysis of the immune cell populations in the tumor microenvironment, specifically targeting natural killer cells, exhausted T cells, B cells, and plasma cells. When your analysis is complete, upload the results to the COMPASS dataset to support the refinement of our treatment response prediction model. Finally, prepare a detailed report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"In my Caucasian female patient with bladder urothelial carcinoma and a tumor mutational burden of 17.0, what is the likelihood of a positive response to Atezolizumab based on the transcriptomic analysis of the tumor immune microenvironment obtained from a nano biopsy?","In my Caucasian female patient with bladder urothelial carcinoma and a tumor mutational burden of 17.0, what is the likelihood of a positive response to Atezolizumab based on the transcriptomic analysis of the tumor immune microenvironment obtained from a nano biopsy? Please access the COMPASS system using your provided username and password. Once logged in, conduct a thorough gene expression analysis on immune cells within the tumor microenvironment, focusing on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload the results to the COMPASS dataset to improve our treatment response prediction model. Finally, compile a detailed report that summarizes the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was conducted using a bladder biopsy, and the tumor mutational burden (TMB) was not determined. Based on these findings, what is the estimated likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was conducted using a bladder biopsy, and the tumor mutational burden (TMB) was not determined. Based on these findings, what is the estimated likelihood of a favorable response to atezolizumab therapy? Please log in to the COMPASS system using your assigned username and password. Once you have accessed the system, perform a comprehensive gene expression analysis of immune cells in the tumor microenvironment, with particular attention to natural killer cells, exhausted T cells, B cells, and plasma cells. Upon completion of your analysis, upload your results to the COMPASS dataset to help enhance our treatment response prediction model. Finally, prepare a detailed report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please log in to the COMPASS system using your assigned username and password. Once logged in, conduct a thorough gene expression analysis of immune cells within the tumor microenvironment, with a particular focus on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, upload your findings to the COMPASS dataset to support improvements in our treatment response prediction model. Finally, compile a detailed report summarizing the key immunological results from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"For my white female patient with bladder urothelial carcinoma (BLCA), considering her transcriptomic tumor immune microenvironment profile from a bladder biopsy and a tumor mutational burden (TMB) of 9.0, what is the likelihood of a positive response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma (BLCA), considering her transcriptomic tumor immune microenvironment profile from a bladder biopsy and a tumor mutational burden (TMB) of 9.0, what is the likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS system using your designated username and password. After logging in, perform a comprehensive gene expression analysis of immune cells in the tumor microenvironment, with particular emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, upload the results to the COMPASS dataset to aid in refining our treatment response prediction model. Finally, prepare a detailed report summarizing the principal immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"For my white female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 5.0. Based on these findings, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 5.0. Based on these findings, what is the estimated likelihood of a positive response to atezolizumab therapy? Please access the COMPASS system using your assigned username and password. After logging in, conduct a thorough gene expression analysis of immune cells within the tumor microenvironment, focusing specifically on natural killer cells, exhausted T cells, B cells, and plasma cells. Once completed, upload your results to the COMPASS dataset to support the enhancement of our treatment response prediction model. Finally, prepare and submit a detailed report summarizing the key immunological findings from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For a White male patient with bladder urothelial carcinoma (BLCA) who underwent a liver biopsy for transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden (TMB) of 5.0, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma (BLCA) who underwent a liver biopsy for transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden (TMB) of 5.0, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please log in to the COMPASS system using your designated username and password. Once you have accessed the system, perform a detailed gene expression analysis of the immune cells within the tumor microenvironment, with a particular emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, upload your findings to the COMPASS dataset to support improvements in our treatment response prediction model. Finally, compile and submit a comprehensive report summarizing the key immunological insights from your analysis.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"For a White male patient with bladder urothelial carcinoma, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and an unavailable tumor mutation burden, how likely is a positive response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and an unavailable tumor mutation burden, how likely is a positive response to Atezolizumab therapy? Please access the COMPASS system using your assigned credentials. Once logged in, conduct a comprehensive gene expression analysis of the immune cells present in the tumor microenvironment, specifically focusing on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, upload your results to the COMPASS dataset to contribute to the refinement of our treatment response prediction model. Finally, prepare and submit a detailed report outlining the significant immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e71235-ar-e712352.pkl. "
BLCA,,,,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is reported as ""nan."" How might these parameters inform the likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is reported as ""nan."" How might these parameters inform the likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS system using your assigned credentials. Once logged in, conduct a detailed gene expression analysis focusing on immune cells within the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload the results to the COMPASS dataset to aid in refining our treatment response prediction model. Finally, prepare and submit a comprehensive report that outlines the significant immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"In a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment has been characterized through a kidney biopsy transcriptomic profile and who presents with a TMB of 7.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","In a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment has been characterized through a kidney biopsy transcriptomic profile and who presents with a TMB of 7.0, what is the estimated likelihood of a positive response to atezolizumab therapy? Please log into the COMPASS system using your assigned credentials. Once logged in, perform a detailed gene expression analysis concentrating on immune cells within the tumor microenvironment—specifically matching natural killer cells, exhausted T cells, B cells, and plasma cells. Upon completion of your analysis, upload the results to the COMPASS dataset to support the refinement of our treatment response prediction model. Finally, prepare and submit a comprehensive report that details the significant immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 1.0. Based on these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 1.0. Based on these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS system using your designated login credentials. After logging in, execute a detailed gene expression analysis with a focus on immune cell subtypes in the tumor microenvironment—including natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is completed, upload your results to the COMPASS dataset to assist in enhancing our treatment response prediction model. Finally, compile and submit a comprehensive report summarizing the key immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma, whose tumor transcriptomic profile of the immune microenvironment is available from a bladder biopsy and for whom the tumor mutation burden could not be determined, what is the likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, whose tumor transcriptomic profile of the immune microenvironment is available from a bladder biopsy and for whom the tumor mutation burden could not be determined, what is the likelihood of a favorable response to Atezolizumab therapy? Please log in to the COMPASS system using your designated credentials. Once you have accessed the system, perform a detailed gene expression analysis with an emphasis on immune cell subtypes in the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, upload your results to the COMPASS dataset to support our treatment response prediction model. Finally, compile and submit a comprehensive report summarizing the key immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a favorable response to atezolizumab therapy? Please log in to the COMPASS system using your assigned credentials. Once you are logged in, conduct a thorough gene expression analysis focusing on immune cell subtypes within the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload the results to the COMPASS dataset to aid our treatment response prediction model. Lastly, prepare and submit a comprehensive report that summarizes the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"For a white female patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 3.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 3.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS system using your designated credentials. Once logged in, perform a detailed gene expression analysis concentrating on immune cell subtypes in the tumor microenvironment, specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload the results to the COMPASS dataset to support the treatment response prediction model. Finally, prepare and submit a comprehensive report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma showing a tumor mutational burden of 7.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma showing a tumor mutational burden of 7.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS system with your designated credentials. After logging in, conduct a comprehensive gene expression analysis that focuses on immune cell subtypes within the tumor microenvironment, specifically natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, upload the results to the COMPASS dataset to contribute to the treatment response prediction model. Finally, compile and submit a detailed report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment transcriptomic profile from a bladder biopsy indicates a tumor mutational burden of 14.0, what is the predicted likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment transcriptomic profile from a bladder biopsy indicates a tumor mutational burden of 14.0, what is the predicted likelihood of a favorable response to Atezolizumab therapy? Please log in to the COMPASS system using your assigned credentials. Once logged in, perform a detailed gene expression analysis concentrating on immune cell subsets within the tumor microenvironment, including natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload the results to the COMPASS dataset to support our treatment response prediction model. Finally, prepare and submit a comprehensive report outlining the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 2.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 2.0 and a transcriptomic profile of the tumor immune microenvironment obtained via kidney biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please sign in to the COMPASS system using your assigned credentials. Once you are logged in, conduct a thorough gene expression analysis specifically focused on immune cell subsets within the tumor microenvironment, including natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, kindly upload the findings to the COMPASS dataset to support our treatment response prediction model. Finally, compile and submit a detailed report that summarizes the principal immunological insights from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, in whom transcriptomic profiling of the tumor immune microenvironment has been performed (with tumor mutational burden data not available), what is the estimated likelihood of a favorable response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, in whom transcriptomic profiling of the tumor immune microenvironment has been performed (with tumor mutational burden data not available), what is the estimated likelihood of a favorable response to atezolizumab therapy? Please log in to the COMPASS system using your assigned credentials. Once you have accessed the system, perform a detailed gene expression analysis of immune cell subsets within the tumor microenvironment. Focus specifically on natural killer cells, exhausted T cells, B cells, and plasma cells. When your analysis is complete, upload the resulting data to the COMPASS dataset to aid our treatment response prediction model. Finally, prepare and submit a comprehensive report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA), a lymph node biopsy was performed to obtain a transcriptomic profile of the tumor immune microenvironment. Given that the tumor mutational burden (TMB) is not available, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA), a lymph node biopsy was performed to obtain a transcriptomic profile of the tumor immune microenvironment. Given that the tumor mutational burden (TMB) is not available, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS system using your designated login credentials. Once logged in, conduct a thorough gene expression analysis of immune cell subsets in the tumor microenvironment, with particular emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload the generated data to the COMPASS dataset to support our treatment response prediction model. Finally, compile and submit a detailed report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a lung biopsy revealed a tumor mutational burden (TMB) of 1.0. Based on these findings, what is his likelihood of responding to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a lung biopsy revealed a tumor mutational burden (TMB) of 1.0. Based on these findings, what is his likelihood of responding to Atezolizumab therapy? Please log in to the COMPASS system using your designated credentials. Once you are logged in, perform a comprehensive gene expression analysis focusing on the immune cell subsets within the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, upload the resulting data to the COMPASS dataset for integration into our treatment response prediction model. Finally, prepare and submit a detailed report outlining the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"In a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 14 and a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy, what is the likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 14 and a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy, what is the likelihood of a positive response to atezolizumab therapy? Please log into the COMPASS system using your assigned credentials. Upon logging in, conduct a thorough gene expression analysis concentrating on the immune cell subsets within the tumor microenvironment—specifically targeting natural killer cells, exhausted T cells, B cells, and plasma cells. Once your analysis is complete, upload the data to the COMPASS dataset for integration into our treatment response prediction model. Finally, compile and submit a comprehensive report detailing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"For a Caucasian male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 14.0 and whose tumor immune microenvironment was profiled from a kidney biopsy, what is the anticipated likelihood of a positive response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 14.0 and whose tumor immune microenvironment was profiled from a kidney biopsy, what is the anticipated likelihood of a positive response to atezolizumab therapy? Please log in to the COMPASS system using your assigned credentials. Once logged in, perform a detailed gene expression analysis focusing on the immune cell subsets within the tumor microenvironment—namely, natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload the resulting data to the COMPASS dataset for use in our treatment response prediction model. Finally, prepare and submit a comprehensive report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"For a Black/African American patient with bladder urothelial carcinoma, a TMB of 9.0, and transcriptomic profiling of the tumor immune microenvironment obtained from a bladder biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a Black/African American patient with bladder urothelial carcinoma, a TMB of 9.0, and transcriptomic profiling of the tumor immune microenvironment obtained from a bladder biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please sign in to the COMPASS system using your designated credentials. Once logged in, conduct a detailed gene expression analysis of immune cell subsets within the tumor microenvironment, specifically focusing on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload the resulting data to the COMPASS dataset to support our treatment response prediction model. Finally, compile and submit a comprehensive report summarizing the key immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"In a White male patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0, based on the transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0, based on the transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS system using your allocated credentials. Once you have signed in, perform a thorough gene expression analysis on immune cell subsets within the tumor microenvironment, with an emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing your analysis, upload the resulting data to the COMPASS dataset to contribute to our treatment response prediction model. Finally, prepare and submit a detailed report highlighting the key immunological findings of your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"For a White female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 7.0 as determined by transcriptomic profiling of the tumor immune microenvironment, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a White female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 7.0 as determined by transcriptomic profiling of the tumor immune microenvironment, what is the expected likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS system using your assigned credentials. Once logged in, conduct a detailed gene expression analysis focusing on immune cell subsets within the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, upload your data to the COMPASS dataset for the treatment response prediction model, and then prepare a comprehensive report summarizing the primary immunological observations from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"For an Asian female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 4.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For an Asian female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 4.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS system using your assigned credentials. Once logged in, perform a thorough gene expression analysis of immune cell subsets in the tumor microenvironment—specifically natural killer cells, exhausted T cells, B cells, and plasma cells. After the analysis is complete, upload your data to the COMPASS dataset for the treatment response prediction model and prepare a detailed report summarizing the main immunological findings from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and who has a TMB of 7.0, what is the likelihood of achieving a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and who has a TMB of 7.0, what is the likelihood of achieving a positive response to Atezolizumab therapy? Please access the COMPASS system using your designated login credentials. Once logged in, conduct a detailed gene expression analysis focusing on immune cell subsets within the tumor microenvironment, specifically examining natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, upload the resulting data to the COMPASS database for use in the treatment response prediction model, and compile a comprehensive report summarizing the key immunological results from your study.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"For my white male patient with bladder urothelial carcinoma, a tumor immune microenvironment transcriptomic profile from a bladder biopsy is available, though the tumor mutational burden (TMB) is not available. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a tumor immune microenvironment transcriptomic profile from a bladder biopsy is available, though the tumor mutational burden (TMB) is not available. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please log in to the COMPASS system using your assigned credentials. After logging in, perform an in-depth gene expression analysis of immune cell subsets within the tumor microenvironment, focusing specifically on natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, upload the resulting data to the COMPASS database for use in the treatment response prediction model and prepare a detailed report summarizing the key immunological findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"For my Caucasian male patient with bladder urothelial carcinoma, given the transcriptomic profile of the tumor immune microenvironment obtained from his bladder biopsy and a tumor mutation burden of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, given the transcriptomic profile of the tumor immune microenvironment obtained from his bladder biopsy and a tumor mutation burden of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS system using your assigned login credentials. Once logged in, conduct a detailed gene expression analysis on immune cell subsets in the tumor microenvironment, with a focus on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, upload the data to the COMPASS database for integration into the treatment response prediction model. Finally, prepare a comprehensive report summarizing the primary immunological findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"For my White female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 7.0, what is the predicted likelihood of a positive response to atezolizumab therapy?","For my White female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 7.0, what is the predicted likelihood of a positive response to atezolizumab therapy? Please use your login credentials to access the COMPASS system. After logging in, perform a detailed gene expression analysis on immune cell subsets within the tumor microenvironment, specifically targeting natural killer cells, exhausted T cells, B cells, and plasma cells. Once the analysis is complete, upload the resulting data to the COMPASS database for integration into the treatment response prediction model. Finally, compile a comprehensive report that outlines the key immunological findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 10.0 and whose transcriptomic tumor immune microenvironment profile was obtained from a separate biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 10.0 and whose transcriptomic tumor immune microenvironment profile was obtained from a separate biopsy, what is the likelihood of a favorable response to atezolizumab therapy? Please log in to the COMPASS system using your credentials. Once logged in, conduct a detailed gene expression analysis of immune cell subsets within the tumor microenvironment, focusing on natural killer cells, exhausted T cells, B cells, and plasma cells. After completing the analysis, upload the resulting data to the COMPASS database to support the treatment response prediction model. Finally, prepare a comprehensive report that summarizes the key immunological findings.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ffa5c7-ar-ffa5c7c.pkl. "
